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Introduction: Lung cancer remains the most common incident form of cancer 
globally, with deaths exceeding those from any other type of malignancy, accounting 
for nearly one in five deaths. Approximately 85% of those cases are non-small-cell lung 
cancers (NSCLCs) and the vast majority of patients presents at advanced stages of 
disease, resulting in an overall five-year survival around 15.9%. Lung cancer is the 
result of a multistep process, in which angiogenesis assumes a major role, allowing 
tumor access to oxygen and nutrients, growth factors and hormones. Antiangiogenic 
strategies are becoming widely used in NSCLC treatment and the pathway involving 
Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) is the main 
target of the approved antiangiogenic molecules (bevacizumab and ramucirumab). 
Nevertheless, the overall survival (OS) benefits from these therapies are modest, 
because a high fraction of tumors is intrinsically refractory to the therapy and a 
substantial proportion of the remaining acquire resistance during treatment. Intensive 
research in this field unveiled some of the mechanisms underneath these 
disappointing results. These include: 1) upregulation of alternative pro-angiogenic 
signalling circuits to overcome VEGF(R) inhibition; 2) recruitment of vascular 
progenitor cells and pro-angiogenic monocytes from the bone marrow and 3) 
alternative mechanism to angiogenesis during tumor development, such as vessel co-
option. Another obstacle in the quest for successful antiangiogenic strategies is the 
lack of reliable predictive biomarkers that may help to tailor patients for whom these 
therapies will be more suited. Angiopoietin-2 (Ang-2), a vessel destabilizing cytokine 
expressed by the endothelial cells, that belongs to the angiopoietin/Tie (type I 
transmembrane tyrosine kinase receptors) axis, works in concert with VEGF in tumor 
angiogenesis, and is now one of the most promising therapeutic targets in 
antiangiogenic strategies. It seems to be largely involved in the proposed escape 
mechanisms to current antiangiogenics and has a major advantage over VEGF, since its 
expression is seldom detected in healthy vasculature and highly regulated at mRNA 
level. These particular characteristics also turn it into an interesting candidate as a 
predictive and prognostic biomarker of outcome in antiangiogenic directed therapies. 
Aims: Evaluation of the correlation between circulating Ang-2 mRNA levels and 
NSCLC prognosis. Also, evaluation of the impact of combined serum levels of VEGF and 
Ang-2 in the prognosis of NSCLC and its potential as diagnostic marker of disease.  
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Material and methods: An unselected cohort of 145 NSCLC cases admitted at 
Portuguese Institute of Oncology of Porto was recruited to the study. 30 control 
individuals, from the same geographical area as case subjects, were also recruited. A 
peripheral blood sample was taken from each individual. mRNA extraction was 
performed from the blood samples, and measured by the quantitative real-time 
polymerase chain reaction (qRT-PCR) method. The serum levels of Ang-2 and VEGF of 
each patient were determined by enzyme-linked immunosorbent assay (ELISA) 
technique prior to treatment.   
Results: There is an association between circulating Ang-2 mRNA levels and OS in 
all stages of NSCLC and higher levels of Ang-2 mRNA correlate with poorer OS. This 
relation is more pronounced when considering only patients eligible for antiangiogenic 
therapies, with stage IV disease. Also, according to the results, circulating Ang-2 mRNA 
levels independently determine OS in NSCLC patients.  
Serum levels of Ang-2 and VEGF are significantly correlated. High serum levels of Ang-2 
and VEGF isolated and both combined (HighAng-2/VEGF) correlate with likelihood of 
presenting NSCLC. Serum levels of Ang-2 and HighAng-2/VEGF, but not VEGF alone, are 
independent prognostic factors for NSCLC. 
Conclusions: This study suggests that circulating Ang-2 mRNA levels could 
successfully be included as predictive biomarkers of response in the design of clinical 
trials involving antiangiogenic drugs targeting Ang-2 and that HighAng-2/VEGF serum levels 
could be exploited as a new valuable integral biomarker in NSCLC. We hypothesise that 
in some NSCLC, tumors obviate the need to generate angiogenesis by co-opting host 
mature vessels and growing along them (vessel co-option). Tumor-co-opted vessel 
interactions result in endothelial cells (ECs) activation and intense Ang-2 expression 
and secretion, leading to vascular disruption and vessel regression, generating a 
hypoxic core in the tumor that is rescued by an increased expression of VEGF, which 
induces a robust angiogenic response. This gives the rationale for therapeutic 
approaches of dual inhibition of Ang-2 and VEGF serving as a launchpad to more 
successful NSCLC anti-vascular treatments. 
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Introdução: O cancro do pulmão permanece a forma mais incidente e letal de 
cancro a nível mundial, com uma taxa de mortalidade que representa 
aproximadamente uma em cada cinco mortes (1.6 milhões de óbitos, no total). Cerca 
de 85% destes casos correspondem a cancros de pulmão de não-pequenas células 
(CPNPCs). O cancro do pulmão resulta de um processo que compreende várias etapas, 
sendo que a angiogénese assume um papel central no desenvolvimento tumoral, 
permitindo o aporte de oxigénio e nutrientes necessários para o crescimento do 
tumor. Actualmente, a terapia com inibidores da angiogénese faz parte das guias de 
tratamento do CPNPC, sendo a via que envolve o Factor de Crescimento do Endotélio 
Vascular (VEGF) e os seus receptores (VEGFRs) o principal alvo dos inibidores 
aprovados até à data (bevacizumab e ramucirumab). No entanto, no que concerne à 
sobrevida global (SG) dos doentes, os benefícios obtidos na prática clínica com estes 
tratamentos têm sido modestos, já que uma fracção importante dos tumores 
apresenta resistência intrínseca à terapia e parte dos restantes adquire resistências ao 
longo do tratamento. Alguns dos mecanismos propostos para justificar estes 
resultados desapontantes incluem: 1) activação de vias de sinalização pro-angiogénicas 
alternativas à via do VEGF(R); 2) recrutamento de células pró-angiogénicas para o 
estroma do tumor e 3) utilização de mecanismos alternativos à angiogénese durante o 
desenvolvimento tumoral, como a co-opção de vasos pré-existentes. Outro obstáculo 
ao sucesso das terapias anti-angiogénicas é a ausência de biomarcadores preditivos 
que possam ajudar a seleccionar doentes para quem estas terapias serão mais 
eficazes. A angiopoietina-2 (Ang-2), expressa pelas células endoteliais (CEs) é 
actualmente investigada como um dos mais promissores alvos da terapia anti-
angiogénica e parece estar envolvida nos mecanismos de evasão aos inibidores de 
VEGF anteriormente descritos. Para além disso, a sua expressão é raramente 
observada nos vasos sanguíneos saudáveis, sendo altamente regulada a nível do ARN 
mensageiro (ARNm). Estas características particulares tornam a Ang-2 um candidato 
interessante a biomarcador prognóstico de SG e preditivo nas terapias dirigidas a alvos 
angiogénicos. 
Objectivos: Avaliação da correlação entre os níveis circulantes de ARNm da Ang-2 
e o prognóstico de doentes com CPNPC. Avaliação do impacto da combinação de níveis 
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séricos de Ang-2 e VEGF no prognóstico do CPNPC e do seu potencial como marcador 
diagnóstico da doença.  
Material e métodos: Participaram neste estudo 145 doentes com CPNPC, 
admitidos no Instituto Português de Oncologia do Porto, e 30 indivíduos saudáveis da 
mesma área geográfica. Foi colhida uma amostra de sangue periférico de cada doente 
à data do diagnóstico, a partir da qual se extraiu ARNm, que foi doseado pelo método 
quantitativo em tempo real da reacção da polimerase em cadeia (qRT-PCR). Os níveis 
séricos de Ang-2 e VEGF de cada doente foram determinados por um método 
enzimático (ELISA).   
Resultados: Os níveis circulantes elevados de ARNm de Ang-2 estão associados a 
menor SG em todos os estadios de CPNPC. Esta relação é ainda mais pronunciada 
quando considerados apenas os doentes com estadio mais avançado (IV) da doença. 
Também se verificou que níveis circulantes elevados de ARNm de Ang-2 constituem 
um factor independente de prognóstico da SG.  
Existe uma correlação directa entre níveis séricos de Ang-2 e VEGF. Quer 
isoladamente quer quando combinados, níveis elevados correlacionam-se com a 
probabilidade de desenvolvimento de CPNPC. Níveis séricos elevados de Ang-2 
isoladamente ou combinados com níveis elevados de VEGF (HighAng-2/VEGF), mas não de 
VEGF isoladamente, são factores de prognóstico para a SG de CPNPC. 
Conclusões: Este trabalho sugere que níveis circulantes de ARNm da Ang-2 
poderão ser incluídos como biomarcadores preditivos de resposta em ensaios clínicos 
que envolvam terapias que tenham como alvo a Ang-2. Sugere também que a 
combinação de níveis elevados de ANG-2 e VEGF no soro possam ser explorados como 
biomarcadores integrais no tratamento de CPNPC com inibidores da angiogénese. 
Também fica a sugestão de que, em alguns CPNPCs, o mecanismo de co-opção de 
vasos pré-existentes do hospedeiro seja a forma preferencial de vascularização do 
tumor, obviando a necessidade de angiogénese. A interacção entre as células tumorais 
e os vasos do hospedeiro resulta na activação das CEs destes vasos, com intensa 
expressão e secreção de Ang-2, conduzindo-os a um estado de dissociação que 
culmina com a regressão dos vasos e com a geração de uma área de hipoxia central, 
que despoleta a expressão de VEGF pelas células do estroma, induzindo uma robusta 
resposta pró-angiogénica. Esta teoria serve de base ao racional para abordagens 
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terapêuticas de inibição dupla de Ang-2 e VEGF, servindo de catapulta para terapias 
anti-angiogénicas de maior sucesso clínico. 
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1. INTRODUCTION 
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1.1 Overview of lung cancer 
Cancer is a major public health issue, representing a leading cause of morbidity 
and mortality worldwide [1].  In 2013, the global incidence of cancer cases was 14.9 
million, with 8.2 million cancer related deaths and, by 2030, an estimated 24 million 
new cases are expected [1,2]. While advances in diagnostics and treatment have led to 
a 3.4-fold increase in patient survival over the last 40 years, many disease settings 
remain with little progress, and with a high rate of recurrence or fatality from 
metastatic disease [3]. 
Lung cancer is the most common incident form of cancer worldwide, with an 
estimated 1.8 million new cases in 2012, with deaths exceeding those from any other 
type of malignancy, accounting for nearly one in five deaths (1.6 million deaths in 
total) [4]. Approximately 85% of those cases are currently classified as Non-Small-Cell 
Lung Cancers (NSCLCs), [5]. The remaining 15% are Small-Cell Lung Cancers (SCLCs), 
extremely aggressive tumors, morphologically and histologically distinct from NSCLCs 
and strongly correlated with cigarette smoking [6]. 
NSCLCs are currently divided in different subsets, according to its histopathological 
characteristics [7]. The two main NSCLC histological phenotypes are adenocarcinoma 
(ADC; ±50%), predominantly more peripheral tumours, thought to arise from the 
alveolar or bronchiolar epithelium (pneumocytes or Clara cells) presenting often 
glandular histology,  and squamous cell carcinoma (SCC; ±40%), which typically arises 
from the bronchial epithelium of the larger, more central airways [5]. Other subtypes 
of NSCLC include large cell carcinoma (LCC; ±3%), which is essentially diagnosed by 
exclusion if tumour cells do not appear glandular or squamous in shape or do not 
express ADC or SCC biomarkers [5,7] and neuroendocrine (NE) neoplasms of the lung, 
including typical and atypical carcinoid tumors and excluding SCLC [8].  
The vast majority of patients with NSCLC presents at an advanced stage of disease, 
when curative treatment is no longer a possibility, resulting in a poor prognosis and an 
overall five year survival around 15.9% [7,9]. This number has only marginally 
improved during the past few decades, despite the increased understanding and 
appreciation of the complexity of NSCLC during this period [9]. 
Current knowledge on the biology of lung cancer shows that it is the result of a 
multistep process, with intricate combinations of morphological, molecular and 
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genetic alterations, ultimately leading to a malignant cell agglomerate bearing the 
phenotypic hallmarks of cancer, defined by Hanahan and Weinberg in 2011 [7,10]. 
Among these, angiogenesis seems to assume major importance, since gaining access 
to the host vascular system and the generation of a tumour blood supply to obtain 
oxygen and nutrients, growth factors and hormones, among others, are rate-limiting 
steps in tumour progression [11]. 
 
1.2 Angiogenesis and cancer 
The identification of massive vascularization in tumors dates to 1863 [12] and the 
importance of tumor angiogenesis has been recognised since 1908 [13], but it was only 
in the early 1970s, with the work of Folkman, that angiogenesis was acknowledged as a 
potential target to inhibit cancer progression [14-17]. The therapeutic potential of anti-
angiogenic strategies boosted this field, and placed angiogenesis as one of the major 
areas of cancer research nowadays.  
It is now widely accepted that most tumors and metastases originate as small 
avascular structures which must induce the development of new blood vessels from 
pre-existing ones, in order to grow beyond a minimum size of 2-3 mm3 [11,18]. To 
achieve this, tumors undergo an angiogenic switch, disrupting the equilibrium between 
pro and anti-angiogenic regulators, favouring pro-angiogenic mechanisms, where 
signalling molecules induce quiescent endothelial cells (ECs) to continually sprout from 
existing blood vessels, forming new vessels that help to sustain expanding neoplastic 
growth [11,19,20], according to the conventional model of angiogenesis, known as 
angiogenic sprout [21]. 
Decades of research investigating the molecular basis of angiogenesis led to the 
discovery of a number of angiogenic molecules that promote tumor angiogenesis [20]. 
Of all the identified angiogenic pathways, the most critical appears to be the one 
involving the vascular endothelial growth factor (VEGF) family and its receptors 
(VEGFR) [22,23].   
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1.2.1 The VEGF family 
The VEGF family consists of five glycoproteins referred to as VEGFA, VEGFB, 
VEGFC, VEGFD and placental growth factor (PIGF) and distinguishes itself from other 
angiogenic super families by the largely non-redundant roles of its members [24]. The 
VEGF ligands bind to and activate three structurally similar type III receptor tyrosine 
kinases (TKR), designated VEGFR1, VEGFR2 and VEGFR3. The assortment of VEGF 
ligands has distinctive binding specificities for each of these TKR, with consequent 
diversity of function [25]. VEGFA and VEGFB have the greatest binding affinity to 
VEGFR1 and 2, with the majority of angiogenic effects being attributable to VEGFA, the 
best characterized of the VEGF family members (from now on referred to as VEGF), 
which is expressed as various isoforms owing to alternative splicing [25]. It stimulates 
angiogenesis in health and disease by signalling through VEGFR2, whose expression is 
restricted primarily to the vasculature and is the key mediator of VEGF-induced 
angiogenesis [25]. VEGFR1 can also bind VEGF, and might function as a decoy receptor 
that sequesters VEGF from VEGFR2 and negatively regulates angiogenesis, [26], 
although its precise role in angiogenesis it is still elusive [24]. The role of PIGF in 
angiogenesis also remains controversial; it exclusively binds to VEGFR1 and it is 
speculated that it may directly stimulate vessel growth and maturation and recruit 
proangiogenic bone marrow-derived progenitors and monocyte-macrophage lineage 
cells [27,28]. The remaining family members, VEGFC and VEGFD, are formed by 
proteolytic processing (unlike VEGFA, B and PIGF, isoforms originated by alternative 
splicing), and bind mainly to VEGFR3, appearing to be important contributors to 
lymphangiogenesis [28]. 
Ever since the identification of VEGF as the first endothelium-acting specific 
cytokine in 1983 [18,29,30], its overexpression has been found in several human 
tumors, including NSCLC [31-35], probably due to its induction under the ischaemic 
conditions that usually occur at the rim of necrotic and hypoxic regions of the tumor 
[11]. A growing number of functions of VEGF in the tumor angiogenic process have 
been unravelled [35]: it triggers multiple signalling networks that enhance ECs 
proliferation and survival, increasing its migration and invasion capabilities, increases 
vascular permeability and interstitial pressure of existing vessels and enhances 
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chemotaxis and mobilization of bone marrow derived endothelial progenitor cells 
(EPCs) into the peripheral circulation [25,36].  
The recognition of the central role of VEGF in tumor angiogenesis turned it into an 
attractive target for therapeutic intervention in cancer and the VEGF pathway became 
the main focus of research in the quest for effective targeted anti-angiogenic 
strategies [29,37]. The extensive investigation in this field has led to the study of 
several anti-angiogenic agents, including monoclonal antibodies to block VEGF and its 
receptor VEGFR2 and VEGFR tyrosine kinase inhibitors (TKIs) [38].  
 
1.3 Anti-angiogenic therapy and lung cancer 
Presently, there are two anti-angiogenic compounds approved by the American 
Food and Drug Administration (FDA) for the treatment of NSCLC. Bevacizumab, an anti-
VEGF recombinant monoclonal antibody that blocks the binding of VEGF to its high-
affinity receptors, was the first angiogenic inhibitor to complete clinical development, 
showing clinical benefit in patients with metastatic colorectal cancer when combined 
with chemotherapy [25,38].   It was approved in 2006 for the treatment of advanced 
non-squamous NSCLC in the first line setting in combination with chemotherapy [35]. 
Later, in 2014, ramucirumab, a fully humanized monoclonal antibody that targets 
angiogenesis by specifically binding to VEGFR-2 with higher affinity than its natural 
ligand VEGF [39], has been approved for the treatment of patients with metastatic 
NSCLC in second line setting, in combination with docetaxel [40]. Besides these two 
anti-angiogenic compounds, many others are currently under clinical evaluation, in 
different stages of clinical trials or waiting for approval for the treatment of metastatic 
or recurrent NSCLC [41,42].  
An important feature that distinguishes the antiangiogenic drugs from other 
targeted therapies is that these agents are typically given to unselected NSCLC patients 
for the approved indications [43] and despite the significant clinical achievements of 
bevacizumab and ramucirumab in different NSCLC treatment settings, the overall 
survival (OS) benefits from antiangiogenic therapies remain modest [44] and these 
VEGF pathway inhibitors are failing to produce enduring clinical responses in most 
patients [21,45]. In a high fraction of them, the tumor is intrinsically refractory to the 
anti-angiogenic therapy such that disease progression continues ceaseless [46] and 
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when this is not the case, acquired resistance to therapy can rapidly occur and limit the 
efficacy of the antiangiogenic treatments [24,47].   
 
1.4 Mechanisms of resistance to antiangiogenic therapy  
Tumor resistance to the antiangiogenic therapies (whether intrinsic or acquired), 
makes the clinical use of VEGF/VEGFR blockers, in patients with advanced NSCLC, more 
challenging than anticipated by the results of preclinical experiments [24]. The modest 
success obtained in the clinical practice raised a number of questions, fuelling this 
already active field of research, to improve anticancer treatment [47,48].  
Researchers are aware that the mechanisms underlying tumor resistance to 
angiogenic inhibitors are complex and diverse, depending upon the location of the 
tumor, the nature of the tumor itself, the surrounding stroma, the dynamic nature of 
the angiogenic process, the strong redundancy determined by a continuous cross-
interaction between main and alternative pathways and the ability to recruit 
proangiogenic bone marrow-derived cells to the tumor site, just to mention a few. 
Until this intricate network underlying tumor resistance is fully understood, and then 
selectively inhibited, it will probably be difficult to achieve the full efficacy of anti-
VEGF(R) and other antiangiogenic therapies [49]. 
In the last few years, some of the explanations to resistance to current 
antiangiogenic therapies have been unveiled and include: 1) upregulation of 
alternative pro-angiogenic signalling circuits to overcome VEGF(R) inhibition; 2) 
recruitment of vascular progenitor cells and pro-angiogenic  monocytes from the bone 
marrow to tumor stroma, where they promote tumor revascularization and growth 
and increased capabilities of invasion without angiogenesis [21,23,24,46,47,50]; 3) 
non-angiogenic tumor microenvironments, as is the case of tumors that do not need 
angiogenic sprout to obtain an efficient blood supply and rather use alternative 
vascularization mechanisms to support its growth [46,47,51]. These comprise NSCLCs 
that grow using pre-existing vessels in the rich vascularized lung, through a vessel co-
option strategy [52]. 
Exhaustive research on this subject reveals that Angiopoietin-2 (Ang-2), a member 
of the Angiopoietin (Ang) -Tie (type I transmembrane tyrosine kinase receptor) system, 
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participates or mediates, at least in part, all of the above proposed mechanisms of 
resistance to angiogenic inhibitors [53].  
 
1.4.1 Angiopoietin-Tie system (Ang-Tie system)  
The human Ang-Tie system was identified in the mid-1990s as a family of growth 
factors essential for blood vessel formation [54]. It consists of two type I 
transmembrane tyrosine kinase receptors (Tie1 and Tie2) and three secreted ligands, 
Ang-1, Ang-2 and Ang-4 [53]. Tie1 and Tie2, with its tyrosine kinase domain in the 
cytoplasm, are preferentially expressed by vascular and lymphatic ECs, although Tie2 
expression has been recorded in non-endothelial cells, both in normal tissue and 
disease, including carcinoma cells and monocytes [55,56]. Unlike Tie1, Tie2 binds 
directly to angiopoietins and has strong kinase activity [57]. Tie1 is currently 
considered an orphan receptor, with no known ligand, but has been shown to bind 
Tie2 and regulate its activity [53,58].  
Ang-1 and Ang-2 are the most extensively characterized ligands of Tie2 and their 
interactions with it comprise an important endothelial cell-specific receptor tyrosine 
kinase signalling system in angiogenesis [54,55,59,60]. They are secreted glycoproteins 
[54], which act primarily in the vasculature to control blood vessel development and 
stability [61] and interact with Tie2 either in a paracrine (Ang-1) or autocrine (Ang-2) 
manner. Although both Ang-1 and Ang-2 have important roles in angiogenesis, the 
nature of their contributions is distinct [53]. 
Studies of loss-of-function have shown that Ang-1-deficient mice present 
embryonic lethal phenotype, due to aberrant vessel remodelling and maturation, 
phenocopying the early midgestation death of Tie2-deficient mice, suggesting that 
Ang-1 is the single, non-redundant, agonist of Tie2 [5,59,62]. Ang-1 is produced 
primarily by perivascular cells (smooth muscle cells, pericytes), although in the adult, it 
is found in many types of tissues and is constitutively secreted in low levels throughout 
the body [63]. Ang-1/Tie2 signaling promotes blood vessel maturation and stabilization 
[64]; at low (basal) levels, Ang-1 engagement with Tie2 activates downstream 
signalling, resulting in EC survival signals, in the maintenance of the endothelial barrier, 
the quiescent state of vasculature and blood vessel assembly, thus ensuring the 
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resting, anti-thrombotic and anti-adhesive state of the vascular endothelium 
[53,59,65].  
Ang-2 is mainly synthesized by ECs and stored in Weibel-Palade bodies in its 
cytoplasm, from where it can be rapidly released upon stimulation to act as an 
autocrine regulator of ECs functions at sites of vascular remodeling [53]. Despite much 
research in the last decade, the role of Ang-2 in the Ang-Tie signaling axis and in 
vascular biology in general, is not as straightforward as the one of Ang-1 [57]. Genetic  
manipulation experiments in mice showed that Ang-2 gain-of-function phenotype 
resembles Ang-1 deficiency in embryonic development, suggesting that it functions as 
a natural antagonist of Ang-1 [59,66], but unlike Ang-1, Ang-2 expression is expendable 
for normal embryonic development, as shown by loss-of-function studies,  although 
Ang-2 deficiency leads to persistent vascular defects after birth [59].  
Along with its prominent role in blood vessel biology during vascular remodeling, 
Ang-2 seems to be an obligate partner of lymphatics maturation. An elegant study 
performed by Gale and co-workers showed that Ang-2 is not required for the initiation 
of lymphatic vascular development, but it is absolutely required for their remodeling 
and normal functioning [67]. Moreover, they found that Ang-2 seemed to substitute 
for Ang-1 agonistic functions in lymphatics in vivo, since lymphatic dysfunction in Ang-
2 deficient mice could be rescued with Ang-1 administration, suggesting that Ang-2 
acts as an activating agonist of Tie2 in this situation [62,67]. 
The dynamic pattern of Ang-2 expression at sites of angiogenesis, such as cyclic 
vessel regression in ovaries, tumor vascular co-option, and hyaloid vessel regression, 
supports the concept that the dominant biologic role of Ang-2 is the control of vascular 
remodeling  through the interruption of Tie2 signaling [54,59,62]; Ang-2-Tie2 
association allows for destabilization of established blood vessels through the 
induction of vessel plasticity (e.g. by decreasing pericyte coverage), disrupting the 
integrity of the blood vessel wall, thereby counteracting vascular normalization, a pre-
requisite for sprouting angiogenesis in the presence of other angiogenic molecules or 
physiologic vascular regression in the absence of such stimuli [68,69]. Moreover, Ang-2 
can exert a direct pro-angiogenic Tie2-independent role by directly binding integrins in 
Tie2 negative ECs, promoting tumor invasion and metastases [61]. 
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1.4.2 Ang-2 and Tie2 expressing-macrophages (TEMs) 
Tie2-expressing monocytes/macrophages (TEMs) are a subpopulation of 
circulating and tumor-infiltrating myeloid cells with inherent vascular growth 
promoting activity, representing a reservoir of cells innately committed to a 
proangiogenic function [70,71]. In human tumors, they are found mainly in 
perivascular and avascular viable areas, but are largely absent in non-neoplastic tissues 
adjacent to the tumor [72]. The preferential location of TEMs in the vicinity of tumor 
blood vessels suggests that these cells may cross-talk with ECs and provide paracrine 
support to nascent blood vessels in these areas during the angiogenic process [72,73]. 
This notion was reinforced by selective elimination of TEMs using a suicide gene 
approach, showing that the absence of TEMs from tumors impairs angiogenesis and 
delays tumor growth, suggesting that these cells have nonredundant, proangiogenic 
activity in tumors [71,74].  
Ang-2 levels in the tumor microenvironment have been directly correlated with 
increased TEMs recruitment to tumor stroma, and it is well established that Ang-2 is 
chemoattractant to TEMs, in a process mediated by Tie2 [70,73,75,76]. The 
overexpression of Ang-2 by ECs and tumor cells exposed to hypoxia, results in greater 
infiltration of TEMs into tumors [72] and in turn, hypoxia induces upregulation of cell-
surface expression of Tie2 in TEMs, increasing their responsiveness to Ang-2, in a 
mechanism of feed-back loop used to amplify TEMs function in tumor 
microenvironment [77]. It is described that stimulation with Ang-2 modulates the 
cytokine profile expressed by TEMs [78], upregulating angiogenic mediators, such as 
the proangiogenic enzymes thymidine phosphorylase (TP) and cathepsin B (CTSB) and 
downregulating the expression of antiangiogenic and immunosuppressive cytokines, 
such as pro-apoptotic tumor necrosis factor-α (TNF-α) and antiangiogenic interleukin-
12 (IL-12) [75,77].  
Although TEMs exhibit some features of M2-polarized tumor-associated 
macrophages (TAMs), a few differences have been found between them. TEMs express 
lower levels of VEGF than TAMs, and do not home to hypoxic, avascular tumor areas. 
Thus, it is likely that TEMs exert a requisite proangiogenic function by supporting 
tumor angiogenesis downstream to VEGF-induced vascular activation, regulating blood 
vessel formation by a VEGF independent pathway [76]. This could explain why the 
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presence of TEMs in the tumors counteracts the efficacy of antivascular treatments 
[73], promoting vascular regrowth following therapy-induced vascular damage and its 
association with the heightened invasive phenotype observed upon the use of anti-
angiogenesis therapies [79].  
 
1.4.3 Ang-2 involvement in alternative pathways of tumor vascularization 
It is fairly recognized that tumor progression is heavily dependent upon 
angiogenesis. However, the model that angiogenesis is necessary for a tumor to 
become larger than a few millimetres and become clinically detectable has been 
challenged by the extensive research in this field, which has shown that angiogenesis is 
not always a pre-requisite for tumor growth [80]. When tumors arise in well-
vascularized organs, their growth will rely on the invasion of host tissue. Enhancement 
of invasion and metastasis facilitates access to normal tissue vasculature, and cancer 
cells stay in close contact with the surface of blood vessels [42,81,82]. This allows 
tumor cells to grow and migrate along quiescent normal vessels and take their oxygen 
and essential nutrients without obligate neovascularization, in a process known as 
vessel co-option [46,47,83]. This procedure has been recognized as an important 
mechanism to establish tumor vasculature, especially in more aggressive tumors, and 
represents a major route for a solid tumor to evade antiangiogenic therapy 
[45,46,51,84]. 
The co-opted vessels are usually supported by pericytes, which stabilize it, while 
promoting endothelial cell survival via induction of autocrine VEGF signalling [85]. In 
vessel co-option, the first tumor-vessel interactions result in ECs activation and intense 
Ang-2 expression and secretion [61]; Ang-2 then acts through an endogenous 
autocrine loop mechanism that is context dependent [65,86]. When it binds to its Tie2 
receptor, it functions as a vessel-destabilizing molecule that converts mature vessels to 
a tenuous and plastic state by inducing loosening of endothelial cell interactions with 
pericytes and smooth muscle cells, leading to the loss of vascular integrity and 
increased vascular permeability that facilitates the infiltration of proteases, cytokines 
and angiogenic myeloid cells, and thus, the priming of the vasculature for a robust 
angiogenic response in the presence of growth factors, such as VEGF 
[18,59,64,65,76,87,88].  
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In the absence of VEGF, as during the early phases of antiangiogenic treatment, 
the expression of Ang-2 causes irreversible loss of vascular structures [87,89] with 
marked regression of the co-opted vessels [53] in a very similar fashion to what 
happens with primitive vessels during development [86]. This generates the hypoxic 
core and the apoptotic tumor cell loss observed in nonangiogenic tumors [84,87], that 
presumably act as de initial stimulus for the molecular changes (which are yet to be 
clarified), that culminate in VEGF expression by the remaining tumor cells and in 
neoangiogenesis [90], mediated both by VEGF and Ang-2 [84].  
 
1.4.4 VEGF and Ang-2-Tie2 axis inhibition 
Ang-2 seems to be a preferential partner of VEGF in the orchestration of tumor 
angiogenesis. Similarly to what is seen with VEGF expression, elevated levels of Ang-2 
have been associated with advanced disease, progression and poor prognosis in the 
most diverse tumor models, including NSCLC [64,90], glioblastoma, gastric, colorectal, 
breast, prostate, kidney and hepatocellular carcinomas, as well as multiple myeloma, 
melanoma, and neuroendocrine tumors [91-99], but unlike VEGF, Ang-2 is seldom 
detectable in healthy vasculature, making it the perfect target to tumor therapy [62]. 
 Considering the multifaceted nature of Ang-2 in tumor angiogenesis promotion 
and its proposed involvement in the mechanisms of resistance to VEGF targeted 
therapies, it is not surprising that, nowadays, Ang-2/Tie2 system is regarded as one of 
the most important therapeutic targets in antiangiogenic strategies. Its inhibition 
would allow both the optimization of current antiangiogenic strategies and the 
circumscription of acquired resistance to approved angiogenic inhibitors 
[53,64,69,76,87,100-107]. Targeting Ang-2/Tie2 axis and VEGF(R) pathway holds the 
promise of more clinically meaningful responses than monotherapies targeting VEGF 
pathway alone [27,53].  
 
1.5 Biomarkers and antiangiogenic therapy 
The missing key to optimize the results obtained with angiogenic inhibitors would 
be the distinction between patients that are likely to respond to these treatments 
from those intrinsically refractory to angiogenic therapies. Predictive biomarkers are 
greatly needed to achieve this goal [108-110]. Despite the several molecular mediators 
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of angiogenesis and inflammatory signalling that have been investigated as potential 
biomarkers of antiangiogenic therapy in NSCLC, no biomarker has yet been 
prospectively validated to correlate with outcomes [111-113]. 
In the future, it is essential that the selection of new antiangiogenic agents to 
enter early pre-clinical trials is based on the availability of identified and validated 
biomarkers predictive of future clinical efficacy [44,109,114].  
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2. OBJECTIVES 
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2.1 General objectives 
- Evaluate the correlation between circulating Ang-2 mRNA levels and NSCLC 
prognosis in an unselected cohort of NSCLC patients.  
- Evaluate the prognostic relevance of serum Ang-2 and VEGF levels in an 
unselected cohort of NSCLC patients. 
 
2.2 Specific objectives 
The aims of this study include: 
- Determination of the independent prognostic value of circulating Ang-2 mRNA 
levels in OS of NSCLC patients, by a quantitative real-time polymerase chain reaction 
(qRT-PCR) method. 
- Investigation of the correlation between serum Ang-2 and VEGF levels in NSCLC 
patients by enzyme-linked immunosorbent assay (ELISA) technique. 
- Assessment of the impact of the combined serum Ang-2/VEGF levels in the 
prognostic of the disease. 
- Evaluation of its potential value as a diagnostic cancer marker 
- Assessment of the influence of the combined serum Ang-2/VEGF levels in the 
susceptibility to NSCLC. 
- Help to establish candidate markers for better prognostication for NSCLC 
patients  
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Ahead to a New Prognostic Factor for NSCLC
Ana L. Coelho1,2*, Anto´nio Arau´jo1,3,4, Mo´nica Gomes1,4, Raquel Catarino1,4, Agostinho Marques2,5,
Rui Medeiros1,4,6
1Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, 2 Faculty of Medicine, University of Porto, Porto, Portugal, 3Medical Oncology
Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, 4Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto,
Portugal, 5 Pulmonology Department, Centro Hospitalar de S. Joa˜o, Porto, Portugal, 6 Research Department, Portuguese League Against Cancer (NRNorte), Porto,
Portugal
Abstract
Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide.
Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers
have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most
beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the
prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined
by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high
circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3
months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is
even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test,
p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c)
index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients’
smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC
patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine
prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our
results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials
involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing
the likelihood of benefit to a level that is acceptable to patients and clinicians.
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Introduction
Non-small-cell lung cancer is the most frequent type of lung
cancer and the most common cause of death from cancer [1]. In
2010, the number of deaths from lung cancer worldwide was 1?5
million, representing 19% of all cancer deaths that year. Most lung
cancers (,80%) are non-small-cell lung cancers (NSCLC) and of
these patients, more than 65% present with locally advanced or
metastatic disease [2].
Solid tumors, including NSCLC, require angiogenesis—the
formation of new blood vessels from existing vessels—for survival,
growth, and metastasis. These new tumor vessels are structurally
and functionally abnormal. They develop by sprouting or
intussusception from pre-existing vessels and exist in a constantly
dynamic state of sprout formation, proliferation, remodeling, or
regression [3,4].
In the last 9 years, antiangiogenic therapy has become part of
standard antitumor treatment. However, the clinical efficacy of
such therapies is limited, and it appears that the full therapeutic
potential of antiangiogenic intervention has not been fully
exploited [5].
It’s now known that there are various molecular players
involved in different mechanisms of vascular growth in solid
tumors, and among these, members of the Vascular Endothelial
Growth Factor (VEGF) and Angiopoietin (Ang) family have a
predominant role [3].
Angiopoietins, the bona fide ligands of Tie-2 receptor, form a
family of secreted 70 kDa glycoproteins acting primarily on the
vasculature to control blood vessel development and stability. Four
distinct angiopoietins have been described: Ang-1, Ang-2, Ang-3
and Ang-4. Angiopoietins bind the second immunoglobulin motif
of Tie-2 whereby they activate Tie-2 and, indirectly, Tie-1 in Tie-
1/Tie-2 heterodimers [6].
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Ang-1 is expressed by pericytes, smooth muscle cells, and
fibroblasts and acts in a paracrine manner. In contrast, Ang-2 is
expressed by endothelial cells (EC) and stored in the Weibel-
Palade bodies from where it can be rapidly released on stimulation
to act as an autocrine regulator of EC functions [7].
Ang-1 and Ang-2 have been described to exert opposing
functions during vessel development. Ang-1–induced Tie2 activa-
tion transduces survival signals and leads to vessel stabilization and
maturation. In turn, Ang-2 acts as a vessel destabilizing agent that
induces permeability and leads to dissociation of cell-cell contacts
in cultured endothelial cells. Genetic experiments have solidly
established Ang-2 as an antagonistic Tie2 ligand [7]. Moreover,
Ang-2 can have a direct pro-angiogenic Tie-2-independent role by
directly binding integrins in Tie2 negative EC [6].
Ang-2 has been implicated in the remodeling of the tumor
vasculature in a process resembling its physiological actions [8,9].
Among the first steps of the angiogenic switch is the co-optive
engagement of the pre-existing host vasculature by the growing
tumor. This results in EC activation and intense Ang-2 expression,
which promotes the dissociation of pericytes from pre-existing
vessels and increases vascular permeability, which facilitates the
infiltration of proteases, cytokines and angiogenic myeloid cells,
and thus, the priming of the vasculature for a robust angiogenic
response in the presence of growth factors, such as VEGF-A [6].
Following the angiogenic switch, the Ang–Tie system contributes,
in concert with VEGF, to tumor angiogenesis [10].
Ang2 is strongly regulated at the transcriptional level. In fact,
almost any form of endothelial cell activation leads to upregulation
of Ang2 mRNA. The mRNA induction of Ang2 in tumor
endothelium has made Ang2 a very attractive circulating
biomarker of angiogenic activation [5].
Some studies have addressed the correlation between Ang-2
expression in tumor tissue and the protein circulating levels and
cancer development and metastasis. However, few clinical studies
have documented a correlation between this molecule and disease
clinical features or prognosis in lung cancer [11-15].
To the best of our knowledge, the present study is the first to
establish a correlation between circulating Ang-2 mRNA levels
and lung cancer prognosis.
Materials and Methods
Ethics statement
The study was conducted according to the principles of the
Helsinki Declaration. The study was approved by the local ethics
committee at the Portuguese Institute of Oncology of Porto
(Portugal). All individuals signed a written informed consent prior
to the inclusion in the study.
Study Population
The study included Caucasian patients from the North region of
Portugal. The inclusion criteria were histological or cytological
confirmed diagnosis of NSCLC, no previous treatment, an Eastern
Cooperative Oncology Group (ECOG) performance status#2
(with 0 indicating that the patient is fully active, 1 that the patient
is ambulatory but restricted in strenuous activity, and 2 that the
patient is ambulatory and capable of self-care but is unable to work
[16]), no prior oncologic disease and available clinical data.
Circulating mRNA levels quantification
Circulating Ang-2 mRNA levels were analyzed by quantitative
real-time PCR (qRT-PCR). Initially, the mRNA was isolated from
the cell fraction of peripheral blood samples by TriPure reagent
(Roche Applied Science), and after separation of the RNA
fraction, the samples were purified using the commercial kit
GeneJET RNA Purification Kit (Fermentas). RNA samples were
then used as templates for cDNA synthesis, using a High Capacity
RNA-to-cDNA Kit (Applied Biosystems), according to the
manufacturer’s instruction. Finally, qRT-PCR was carried out
on a StepOne TMOne qPCR equipment, containing 1x Master
Mix (Applied Biosystems), with 1x probe (TaqMan Gene
Expression Assay with reference number Hs 01048042_m1,
Applied Biosystems), cDNA sample, human GUSB (Beta Glucu-
ronidase) and human b-2M (b-2 Microglobulin) endogenous
controls (both from Applied Biosystems) according to manufac-
turer’s instructions.
To quantify the amplified transcripts, we used the comparative
CT (22DDCT) method [17]. In accordance with the method, the
mRNA amounts of the target gene (Ang-2) were normalized to two
endogenous controls and relatively to a calibrator. We used the
housekeeping genes GUSB (Applied Biosystems) and b-2M
(Applied Biosystems) as internal controls and commercial RNA
controls as calibrators (Applied Biosystems). DDCT represents the
difference between the mean DCT value of a patient blood sample
and the mean DCT value of the calibrator, both calculated after
the same PCR run, whereas DCT is the difference between the
CT of the target gene and the CT of the endogenous reference
gene of the same sample. The relative quantitative value was
expressed as 22DDCT. Relative quantification (RQ) based on the
Ct (the number of PCR cycles necessary to obtain the threshold
signal of fluorescence) values was analyzed using Applied
Biosystems StepOne Software v 2.2. All samples were run in
duplicate.
Statistical analysis
Ang-2 mRNA expression levels were considered as categorical
variables using the first quartile as cut-off point. We defined that
the values under the cut-off point should be included in the low
expression group and that all the other cases above the cut-off
point constituted the high expression group. Overall Survival (OS)
was calculated from the beginning of treatment to death from any
cause. Median OS was estimated with the Kaplan-Meier method
and compared with a two-sided log-rank test. Multivariate Cox
proportion analysis was performed to determine the influence of
age, gender, tumor stage, histological type, smoking status and
circulating Ang-2 mRNA levels on OS in NSCLC patients.
Hazard ratios (HRs) estimated from the Cox analysis were
reported as relative risks with corresponding 95% confidence
intervals (CIs). The extent of discrimination of the predictive
ability was quantified using the Harrel’s concordance index (c-
index), which estimates the probability of concordance between
predicted and observed responses. The interpretation of the C
index is similar to the interpretation of the area under a receiver
operating curve (ROC) curve. A value of 1.0 indicates that the
features of the model perfectly separate patients with different
outcomes while a value of 0.5 indicates the features contain
prognostic information equal to that obtained by chance alone.
All analyses were performed using Statistical Package for Social
Science (SPSS) for Windows version 18 (Chicago, IL). The level of
statistical significance was set at 5% (P#0.05).
Results
The study included 92 Caucasian individuals from the North
region of Portugal, with histopathological diagnosis of NSCLC,
with a mean age of 63.2 years610.7. The blood samples were
collected at the time of diagnosis, before treatment, and included
33 squamous cell carcinomas (SCC), 46 adenocarcinomas, 11
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undifferentiated NSCLC, 1 large cells and 1 mixed carcinomas, of
which 77,0% were male and 75,8% smokers or former smokers,
divided in 42 non-metastatic and 50 metastatic cases (Table 1).
Our results demonstrate that patients with high circulating Ang-
2 mRNA levels have diminished overall survival when compared
to those with low mRNA expression (20.3 months vs 34.3 months,
respectively; Log Rank Test, p = 0.016) (Figure 1). Moreover,
when considering only stage IV patients, the most suitable
candidates to antiangiogenic treatment, the range interval between
overall survival in the high and low settings of Ang-2 mRNA
expression augments (15.9 months vs 31.3 months, respectively;
Log Rank Test, p = 0.036) (Figure 2).
To determine the independent prognostic value of circulating
Ang-2 mRNA levels for OS, a multivariate analysis using a Cox
proportional hazard model was performed. In the multivariate
analysis that included age, gender, tumor stage, histological type,
smoking status and circulating Ang-2 mRNA levels, we identified
tumor stage, smoking status and Ang-2 mRNA levels as
independent prognostic factors for OS in NSCLC patients
(Table 2).
Attending to these results, we performed an analysis considering
four different prognostic models to ascertain the predictive power
of circulating Ang-2 mRNA levels in the clinical outcome of
NSCLC patients (Table 3). In the first two models, we considered
the predictive ability of tumor stage and smoking status (c-index
0.657 for tumor stage and 0.522 for smoking status) (Model 1 and
Model 2). Model 3 addressed the question whether circulating
Ang-2 mRNA levels could also be considered a prognostic factor
in NSCLC, with a c-index of 0.629 (Model 3). In model 4, we
created a three variables prognostic nomogram congregating the
three aforementioned models. The prognostic predictive ability
was increased when adding circulating Ang-2 mRNA levels, with a
c-index of 0.798 (Model 4).
Discussion
Many predictive and prognostic markers have been assessed in
NSCLC but, until the discovery of the importance of Epidermal
Growth Factor Receptor gene (EGFR) [18], no single molecular
marker had proven to be useful for either patient selection or
selection of specific drugs. The TNM classification (lung cancer
staging) has stood the test of time and to date, no other prognostic
factors beyond it have been prospectively validated, remaining the
most powerful prognostic instrument in lung cancer [19,20].
Hence, the identification of other prognostic factors that can be
integrated with TNM to create a composite prognostic index for
NSCLC would be clinically useful.
Many clinical trials have demonstrated the importance of
evaluating several molecular biomarkers of NSCLC tumor
specimens to allow a personalized medicine, enhancing progres-
sion free survival and overall survival times, diminishing side
effects, giving patients a better quality of life and enabling to
perform more cost-effectiveness treatments [21]. Moreover, we
now know that in addition to predictors of response, these genes
can also be regarded as prognostic factors for NSCLC [21],
making the evaluation of these biomarkers the state of the art of
the advanced or metastatic NSCLC treatment. However, only
patients with lung adenocarcinoma with EGFR mutations or
anaplastic lymphoma kinase (ALK) rearrangements have an FDA-
approved therapy available [18,21–23]. Unfortunately, for squa-
mous cell NSCLC the scenario is even more shadowy. Although
this is an important field where novel targeted therapies are
currently under investigation, the disease prognosis still remains
disappointing.
As the field of lung cancer moves further into the age of
personalized medicine, alternative targets continue to be investi-
gated, since it has become clear that it will be imperative to target
the tumor stroma and surrounding environment and not merely
the genes’ mutations within the cancer cells itself. The main goal of
this quest is to identify a pan-NSCLC prognostic factor that can
also help to predict treatment response and monitor tumor
progression. One of the most extensive studied of such alternative
targets is angiogenesis, a necessary process in the growth and
metastasis of all solid tumors [23]. Preclinical models and selected
clinical trials showed benefits for targeting angiogenesis in lung
cancer, with antiangiogenic treatment emerging as the first
effective anti-stroma therapy to complement the established
antitumor therapies [7]. So far, only VEGF, the master switch
of the angiogenic cascade, has been validated as a therapeutic
target for antiangiogenic intervention [7] but no published clinical
study has proved that circulating levels of this target are prognostic
factors in patients with NSCLC subjected to antiangiogenic
therapy [24].
Despite of the advances into the elucidation of the tumor milieu
in general and tumor angiogenesis in particular, there is a
significant knowledge deficit in the understanding of the molecular
basis of antiangiogenic therapy and the related adverse events seen
with these agents [23]. Researchers have been searching for
potential biomarkers to identify patients for whom therapy with
antiangiogenic inhibitors may be most beneficial and the
importance of these as prognostic factors in NSCLC.
Whereas VEGF is abundantly expressed by the tumor cells in
most tumors, Ang-2 is mostly expressed by the tumor-associated
endothelium [7]. Moreover, unlike VEGF, Ang-2 shows limited
Table 1. NSCLC patients’ characteristics.
Patients
(n =92)
n %
Gender
Female 21 22.8
Male 71 77.2
Age
Mean6S.D. 63.2610.7
Histology
Adenocarcinoma 46 50.0
SCC 33 35.8
NSCLC NOS 11 12.0
Large Cells
Mixed
1 1.10
1 1.10
Staging
I 3 3.30
II 1 1.10
III 38 41.3
IV 50 54.3
Smoking status
Non-smoker 22 23.9
Smoker 48 52.2
Former smoker 22 23.9
doi:10.1371/journal.pone.0090009.t001
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postnatal expression in normal tissues and its broad expression and
prominent upregulation in tumor milieu turns it in the perfect
candidate to help to define prognosis in solid tumors, besides being
a suitable suspect in the game of antiangiogenic strategies [7,25].
In the present study, we aimed to evaluate the prognostic
significance of Ang-2 mRNA detection in the cell fraction of
peripheral blood of patients with NSCLC prior to treatment, using
qRT-PCR. Moreover, we wanted to assess the possibility of using
it as a prognostic factor that could be adjoined to NSCLC staging
to create a composite prognostic index for NSCLC and created a
nomogram that predicts the influence of circulating Ang-2 mRNA
levels in NSCLC clinical outcome.
Our results demonstrate that high circulating Ang-2 mRNA levels
are a significantly unfavorable prognostic factor in NSCLC overall
survival. Patients with high circulating Ang-2 mRNA levels have
diminished overall survival when compared to those with lowmRNA
expression, when considering all NSCLC stages and this difference is
even bigger when considering only patients with distant metastasis,
the most suitable candidates to antiangiogenic therapies. Moreover,
mRNA levels independently determine survival, and its prognostic
predictive ability increases when modeled in a simple and easy to
apply nomogram with NSCLC staging, patients’ smoking status and
Ang-2 mRNA levels (c-index 657 vs c-index 0.798, respectively).
Figure 1. Association of high and low circulating levels of Ang-2 mRNA with overall survival in NSCLC by Kaplan-Meier curves.
doi:10.1371/journal.pone.0090009.g001
Figure 2. Association of high and low circulating levels of Ang-
2 mRNA with overall survival in stage IV NSCLC by Kaplan-
Meier curves.
doi:10.1371/journal.pone.0090009.g002
Table 2. Multivariate Cox regression analysis for predictable
factors of overall survival.
HR 95% CI P
Age ($63;,63) 0.97 0.0.610–1.55 0.905
Gender 0.55 0.260–1.16 0.118
Tumor stage 1.79 1.12–2.88 0.016
Histological type 1.12 0.810–1.53 0.503
Smoking status 2.36 1.09–5.09 0.029
Ang-2 mRNA 2.04 1.13–3.67 0.017
doi:10.1371/journal.pone.0090009.t002
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Taken together, these results prompt us to think that detection
and quantification of circulating Ang-2 mRNA in blood samples,
along with proper NSCLC staging, could serve as a unique and
practical diagnostic tool to determine prognosis in NSCLC.
Circulating Ang-2 mRNA levels samples are a simple to obtain
factor which can theoretically reflect the overall angiogenic activity
of the tumor and offers a huge advantage over tissue based
markers, including the ability to carry out continuous, noninvasive
assessments over time and most important, not relying on the
availability of adequate surgical or biopsy specimens of NSCLC.
Various therapeutic agents targeting Ang-2 have been described
and are being evaluated in early-phase clinical trials [5,9,25–28].
Albeit antiangiogenic drugs are efficacious in unselected popula-
tions, increasing market competition between targeted therapies is
likely to drive the growth of individualized chemotherapy, with a
central role for biomarkers. Although more studies are needed to
confirm this hypothesis, the circulating Ang-2 mRNA levels could
be strong candidates for predicting the survival benefit associated
with the targeted therapies currently under evaluation and should
be included in the design of preclinical studies and clinical trials
involving antiangiogenic drugs targeting Ang-2, to guide adequate
patient stratification and dose selection and increasing the
likelihood of benefit to a level that is acceptable to patients and
clinicians.
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Aim: Evaluate if serum levels of VEGF and Ang-2 are correlated in non-small-cell lung cancers 
(NSCLCs) and its implications in the diagnostic and prognostic of the disease. Patients & 
methods: Unselected cohort of 145 NSCLC patients and 30 control individuals. The serum 
levels of Ang-2 and VEGF of each patient were measured by ELISA prior to treatment. Results 
& conclusions: Serum levels of Ang-2 and VEGF are correlated (p < 0.0001). High serum levels 
of Ang-2 and VEGF isolated and both combined (highAng-2/VEGF) correlate with likelihood of 
presenting NSCLC (p = 0.016; p = 0.003; p < 0.0001, respectively). Serum levels of Ang-2 and 
highAng-2/VEGF but not VEGF alone are independent prognostic factors (p = 0.001; p = 0.619; 
p = 0.005). HighAng-2/VEGF serum levels could be exploited as a new valuable integral biomarker 
in NSCLC.
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Lung cancer is one of the leading causes of death from cancer worldwide. In 2008, it was the most 
commonly diagnosed cancer as well as the principal cause of cancer death in males globally and it 
was the fourth most commonly diagnosed cancer and the second cause of cancer death in females [1]. 
Most lung cancers (∼80%) are non-small-cell lung cancers (NSCLCs) and of these patients, more 
than 65% present with locally advanced or metastatic disease [2].
The advent of targeted agents that inhibit tumor specific biological pathways opened the door for 
a new era of NSCLC treatment. However, only EGFR mutations (∼10–15% in the occidental popu-
lation) or anaplastic lymphoma kinase rearrangements (∼3–5% in the occident) have a US FDA-
approved therapy available [3]. Alternative targets continue to be investigated and one of the targeted 
approaches most widely studied in the treatment of NSCLC is the inhibition of angiogenesis [4].
Abnormal angiogenesis, characterized by an increase in the number of proliferating endothelial 
cells and altered morphology of the vasculature, is a hallmark of cancer [5]. VEGF has long been 
regarded as the master switch of angiogenesis induction, orchestrating early events of the angiogenic 
cascade, such as directional sprouting and endothelial cell proliferation [6–8]. There is also a wealth 
of evidence supporting the role of VEGF as a potent regulator of solid tumor angiogenesis, including 
NSCLC: VEGF is strongly expressed in tumors from patients with NSCLC and correlates strongly 
with microvessel density, survival and postoperative relapse [9]. Despite its requisite to vascular 
formation, VEGF needs to work in concert with other factors and several studies suggest that the 
angiopoietins are among its p referential partners [6,10].
For reprint orders, please contact: reprints@futuremedicine.com
Future Oncol. (2015) 11(24)3234
RESEaRch aRticlE Coelho, Araújo, Gomes et al.
future science group
Ang-1 and Ang-2 are secreted factors that bind 
to the endothelial cell-specific receptor tyrosine 
kinase Tie2 [11]. Angiopoietin/Tie2 signaling sys-
tem is essential for vascular development and func-
tion [12]. Ang-1 is a strong Tie2 agonist that is pro-
duced primarily by perivascular cells, and Ang-1/
Tie2 signaling is believed to promote blood ves-
sel maturation and stabilization [11]. By contrast, 
Ang-2 expression is tightly regulated, and it is syn-
thesized and secreted primarily by endothelial cells 
(EC) at sites of vascular remodeling and is believed 
to function largely as a Tie2 inhibitor, blocking 
Ang-1 function, disrupting the integrity of the 
blood vessel wall and inducing a state of vascular 
plasticity, thereby counteracting vascular normali-
zation, which conducts to angiogenesis [13,14].
Insights into tumor angiogenesis have shown 
that VEGF and Ang-2 act in concert during 
tumor vascular development [10,15]. Following the 
angiogenic switch when proangiogenic stimuli 
for new vessel formation become dominant over 
naturally occurring angiogenesis inhibitors and 
tumor changes from an avascular state to an angi-
ogenic phenotype [8,16], there is the activation of 
EC and intense Ang-2 expression, which leads 
to EC apoptosis and the regression of co-opted 
blood vessels. This secondary avascular tumor 
experiences profound hypoxia, which upregulates 
VEGF expression to induce robust angiogenesis 
at the tumor margin. In the presence of VEGF, 
Ang-2 enables EC migration, proliferation and 
sprouting of new vessels [12].
Many biomarkers of angiogenesis have been 
proposed and investigated as diagnostic and prog-
nostic markers in cancer, but despite extensive 
research, none has yet been validated for routine 
clinical use [9,17].
As agents targeting Ang-2, alone or in com-
bination with VEGF inhibition, are currently 
in Phase I and Phase II trials [18,19], we aimed 
to evaluate the prognostic relevance of serum 
Ang-2 and VEGF levels in an unselected cohort 
of NSCLC patients. Based on the proposed 
interplay between VEGF and Ang-2, it was also 
examined if there was a co-dependent relation 
in both molecules serum levels and whether the 
combination of both had a diagnostic and/or 
prognostic impact in NSCLC patients or in the 
susceptibility for NSCLC development.
Patients & methods
●● Study population
The study included 145 newly diagnosed and 
untreated Caucasian NSCLC patients, from 
the north region of Portugal, admitted to the 
Portuguese Institute of Oncology of Porto, and a 
control group with 30 healthy individuals from 
the same geographic area. Patients’ recruitment 
started in 2006 and the inclusion criteria were 
histological or cytological confirmed diagnosis 
of NSCLC, no previous treatment, an Eastern 
Cooperative Oncology Group (ECOG) per-
formance status ≤2 (with 0 indicating that the 
patient is fully active, 1 that the patient is ambu-
latory but restricted in strenuous activity and 2 
that the patient is ambulatory and capable of 
self-care but is unable to work) [20], no prior 
oncologic disease and available clinical data. 
None of the patients performed antiangiogenic 
therapy. All the patients were chemonaive by 
the time of sampling collection and performed 
chemotherapy as first-line treatment or in com-
bination with surgery. The patients included in 
this study were treated according to the guide-
lines at the time of the study, namely in first 
line with a platin-based doublet chemotherapy 
in combination with a third-generation cyto-
toxic compound such as paclitaxel, gemcitabine 
or pemetrexed. In second and posterior lines, 
they were treated with docetaxel, pemetrexed 
or erlotinib.
The control group consisted of presum-
ably Caucasian healthy individuals, recruited 
from the blood donor bank of the Portuguese 
Institute of Oncology of Porto, free of malign, 
i nflammatory and connective tissue diseases.
●● Serum Ang-2 & VEGF analysis
All study participants had venous blood sam-
ples drawn before any treatment. Blood samples 
were collected in CTAD tubes to avoid platelet 
and leukocyte secretion of VEFG [21]. All the 
samples were collected in the morning, after an 
overnight fasting and allowed to rest for 1 h, 
at room temperature, before processing. These 
were centrifuged at 1000× g for 10 min followed 
by serum collection. Serums were aliquoted and 
stored at -20ºC until analyses were performed. 
The scientists were blinded to the outcome of 
the individual patient.
Serum levels of VEGF and Ang-2 were meas-
ured by means of an ELISA using the Quantikine 
Human VEGF ELISA kit (catalog #DVE00) and 
the Human Angiopoietin-2 Quantikine ELISA 
kit (catalog #DANG20), respectively (both were 
purchased from R&D Systems, Inc., MN, USA), 
according to manufacturer’s protocol. Optical 
density was measured as the end point for the 
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concentration in each well. Standard curves for 
each analyte were generated in duplicate on the 
same plates as the specimens and used to extrapo-
late the concentrations of the specific analytes 
using the average value for each sample after sub-
tracting the background absorbance. All speci-
mens were assayed twice and the average of the 
two measurements was used in the data analysis. 
The minimum detectable levels of Ang-2 and 
VEGF were 1.2 and 9.0 pg/ml, respectively.
●● Statistical analysis
The Spearman correlation coefficient test was 
applied to assess the relationship between Ang-2 
and VEGF serum levels. These levels were con-
sidered as categorical variables using the mean 
values obtained to the control group as cut-off 
points.
Chi-square analysis was used to compare cat-
egorical variables and a 5% level of significance 
was used in the analysis. The odds ratio (OR) 
and its 95% CI were calculated as a measure-
ment of the association between the amount of 
Ang-2 and VEGF and the probability of lung 
cancer presence. Multivariate logistic regression 
analysis was used to calculate the adjusted OR 
(aOR) and 95% CI, with adjustment for age, 
gender and smoking status.
For the diagnostic discrimination of serum 
Ang-2 and VEGF between cancer patients and 
controls, the area under the curve of the receiver 
operating characteristic curve (AUC–ROC) was 
assessed nonparametrically. A p-value ≤ 0.05 was 
regarded as significant. An AUC-ROC equal 
to 1 denotes perfect discrimination between 
patients with cancer and patients without cancer, 
a value equal to 0.5 denotes the lack of discrimi-
nation, and values in between indicate a degree 
of  discrimination between strong and poor.
Overall survival (OS) was calculated from 
the beginning of treatment to death from any 
cause. Median OS was estimated with the 
Kaplan–Meier method and compared with a 
two-sided log-rank test. Multivariate Cox pro-
portional hazard regression was performed to 
evaluate Ang-2 and VEGF serum levels and 
NSCLC survival while adjusting for age, gender, 
smoking history, histological type and clinical 
stage. Hazard ratios (HRs) estimated from the 
Cox analysis were reported as relative risks with 
c orresponding 95% CIs.
The predictive discriminative ability of regres-
sion models was quantified using the Harrel’s 
concordance index (c‐index). C-index estimates 
the probability of concordance between pre-
dicted and observed results and its interpretation 
is similar to the one of the area under a receiver 
operating curve (ROC) curve. A value of 1.0 
indicates that the features of the model perfectly 
separate patients with different outcomes while 
a value of 0.5 indicates that the features contain 
prognostic information equal to that obtained 
by chance alone.
All analyses were performed using Statistical 
Package for Social Science for Windows ver-
sion 18 (Chicago, IL, USA). The level of  statistical 
significance was set at 5% (p ≤ 0.05).
Results
Serum samples were collected from 145 NSCLC 
patients enrolled in this study (prior to treatment, 
at the time of diagnosis) and 30 control individ-
uals, from March 2006 until September 2011. 
The median follow-up duration was 22 months 
(range: 1–63 months).
Table 1 summarizes the baseline characteris-
tics of the lung cancer patients and the controls 
included in this study.
●● Serum Ang-2 & VEGF in NSCLC patients 
& healthy control individuals
Median serum level of Ang-2 in NSCLC 
patients was 3432.5 pg/ml (values ranged from 
Table 1. Baseline characteristics of non-small-cell lung cancers patients and 
controls.
Characteristics Patients (n = 145), n (%) Controls (n = 30) , n (%)
Gender: 
 – Female 
 – Male
  
33 (22.8) 
112 (77.2)
  
6 (20.0) 
24 (80.0)
Smoking status: 
 – Smokers/former smokers 
 – Nonsmokers 
 – Not stated
  
105 (72.4) 
36 (24.8) 
4 (2.80)
  
24 (80.0) 
6 (20.0) 
Age (years): 
 – Mean ± standard deviation
  
63.8 ± 10.3
  
58.7 ± 4.63
Histology: 
 – Adenocarcinoma 
 – SCC 
 – NSCLC NOS 
 – Large cells 
 – Mixed
 
72 (49.6) 
51 (35.2) 
19 (13.1) 
2 (1.4) 
1 (0.7)
   
Staging: 
 – I 
 – II 
 – III 
 – IV 
 – Not stated
 
6 (4.1) 
3 (2.1) 
65 (44.8) 
70 (48.3) 
1 (0.7)
   
NOS: Not other specified; NSCLC: Non-small-cell lung cancer; SCC: Squamous cell carcinoma.
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Figure 1. Receiver-operating characteristics curves to calculate sensitivity and specificity 
of (A) Ang-2, (B) VEGF and (C) combined Ang-2 and VEGF serum levels as tumor markers of 
non-small-cell lung cancers. 
AUC: Area under the curve; ROC: Receiver-operating characteristics.
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650.0 to 14050.0 pg/ml) and was higher than 
the median of the control group, 2710.0 pg/ml 
(values between 1290.0 and 8440.0 pg/ml). 
Median serum level of VEGF was also higher 
in patients with lung cancer, 521.0 pg/ml (values 
ranged from 25.0 to 5171 pg/ml) than in the 
control group, 209.5 pg/ml (ranging from 4 to 
1074 pg/ml). In all patients with lung cancer, 
serum Ang-2 was significantly correlated with 
serum VEGF with a Spearman’s correlation 
coefficient of r = 0.325 (p < 0.0001).
●● Diagnostic performance of serum Ang-2 
& VEGF in NSCLC
The ROC curves were made to evaluate the 
diagnostic power of the serum Ang-2 and VEGF 
concentrations isolated and the combination of 
both markers. (Figure 1A–C). The ROC analysis 
is performed through the study of the function 
that links the sensibility with 1 - specificity. The 
subtended area under the ROC curve (AUC) 
shows a synthetic index of the overall capacity of 
the test in differentiating between healthy and ill 
individuals. The closer the area gets to the unit, 
the greater its discriminating ability. According to 
our data, the AUC for Ang-2 is 0.670 (95% CI: 
0.57–0.68; p = 0.003) and the AUC for VEGF 
is 0.693 (95% CI: 0.59–0.79; p = 0.001). We 
defined a biomarker index (BI
Ang-2*VEGF
) combin-
ing both markers (multiplying each level of Ang-2 
for the corresponding level of VEGF in the same 
patient = Ang-2 × VEGF), and the AUC obtained 
is 0.739 (95% CI: 0.65–0.83; p < 0.0001). We 
found that lower cut-off values increased the 
sensitivity of the assay but at the cost of specific-
ity and vice versa. Using the results of the ROC 
curves, an analysis was made on the test perfor-
mance with respect to the different cut-off val-
ues (Table 2). The results showed that, for Ang-2, 
considering the cut-off value of 2710 pg/ml (equal 
to median value observed in the healthy control 
group), there is a probability of illness of 87.5% 
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when the test is positive (PPV). An Ang-2 cut-off 
level = 2710 pg/ml differentiated between lung 
cancer patients and controls with a specificity 
of 50.0% and sensitivity of 72.0%. For VEGF, 
considering the cut-off value of 209 pg/ml (equal 
to median value observed in the healthy control 
group), there is a probability of illness of 88.1%, 
when the test is positive (PPV). A VEGF cut-off 
level = 209 pg/ml differentiated between lung 
cancer patients and controls with a specificity of 
50.0% and sensitivity of 77.1%. For the combi-
nation of Ang-2 and VEGF levels, with a cut-off 
level of 566.7 × 103 pg/ml (209 × 2710 pg/ml), 
there is a probability of illness of 86.9% when 
the test is positive (PPV). A BI
Ang-2*VEGF
 cut-off 
level = 566.7 × 103 pg/ml differentiated between 
lung cancer patients and controls with a specificity 
of 77.8% and sensitivity of 43.3%.
●● Serum Ang-2 & VEGF levels & likelihood of 
presenting NSCLC
To address the question whether or not serum 
levels of Ang-2 and VEGF are associated with 
NSCLC, we dichotomized our samples in 
high and low serum levels subgroups, using 
the median values of the healthy control group 
as cut-off points (2710 pg/ml for Ang-2 and 
209 pg/ml for VEGF). Therefore, we defined a 
high Ang-2 group (high Ang-2 >2710 pg/ml) and 
a high VEGF group (high VEGF >209 pg/ml) 
and the low serum levels groups (low Ang-2 
≤2710 pg/ml and low VEGF≤209 pg/ml). 
Moreover, since we observed that serum Ang-2 
expression levels were significantly correlated 
with serum VEGF expression levels (r = 0.325; 
p < 0.0001), we grouped all the samples with 
both high Ang-2 and high VEGF in a different 
setting (>2710 and >209 pg/ml, respectively), 
which we termed high
Ang-2/VEGF
 and compared it 
with all the other samples regarding the risk of 
presenting NSCLC.
Our results show that individuals with high 
Ang-2 or high VEGF serum levels have higher 
probability of presenting NSCLC than indi-
viduals with low serum levels (OR: 2.63, 95% 
CI: 1.18–5.86, p = 0.016; OR: 3.27, 95% CI: 
1.45–7.36, p = 0.003, respectively). Moreover, 
we observed that individuals with high
Ang-2/VEGF
 
present an almost fivefold increased likelihood of 
having NSCLC (OR: 4.66, 95% CI: 1.88–11.5, 
p < 0.0001). Multivariate logistic regression anal-
ysis shows that this risk remains statistically sig-
nificant for the three groups defined, re gardless of 
age, gender and smoking status (Table 3).
●● Serum Ang-2 & VEGF levels & NSCLC 
clinical outcome
To evaluate the role of serum Ang-2 and VEGF 
levels in overall survival (OS) of NSCLC 
patients, we used the same subgroups of the 
above analysis (high Ang-2 or high VEGF and 
low Ang-2 or low VEGF serum levels), as well 
as the high
Ang-2/VEGF
 setting plotted versus all the 
other samples (Figure 2A–C).
Our results demonstrate that patients with high 
Ang-2 serum levels have diminished OS when 
compared with those with low Ang-2 (21.0 vs 42.6 
months, respectively; log rank test, p = 0.001) 
(Figure 2A). There is no statistically significant 
association between VEGF high and low serum 
expression levels and OS in our group of NSCLC 
patients (22.9 vs 30.7 months, respectively; log 
rank test, p = 0.619) (Figure 2B). Interestingly, 
when comparing the setting of high
Ang-2/VEGF
 phe-
notype against all other samples, we observed 
a decrease in OS in both groups (19.1 vs 35.2 
months, respectively; log rank test, p = 0.005) 
(Figure 2C), suggesting that when both Ang-2 and 
VEGF are elevated in serum, the effect in OS of 
NSCLC patients is more pronounced than the 
elevation of each marker by itself.
To determine the independent prognostic value 
in OS of serum Ang-2 and VEGF expression lev-
els, using the above described approach, a mul-
tivariate analysis with Cox proportional hazard 
Table 2. Test performance for serum Ang-2, VEGF and BIAng-2*VEGF.
Cut-off value (pg/ml) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Ang-2 
325.0 100 3.3 83.3 100
2430 80.7 43.3 87.3 31.7
2710 72.0 50.0 87.5 27.3
3032.5 64.1 60.0 88.6 25.7
6962.5 13.1 96.7 95.0 18.7
VEGF
0.5 92.4 23.3 85.3 38.9
150.5 81.9 40.0 86.8 31.6
209.0 77.1 50.0 88.1 31.3
266.5 72.9 60.0 89.7 31.6
858.5 21.7 90.0 92.9 20.5
1069.0 18.1 96.4 96.3 18.6
BIAng-2*VEGF/10
3
7.992 92.4 30.0 86.4 45.0
202.3 89.6 36.7 87.2 42.3
566.7 77.8 43.3 86.9 29.6
987.6 62.5 66.7 90.0 27.0
9760 8.33 100 100.0 18.5
NPV: Negative predictive value; PPV: Positive predictive value.
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model was performed. In the multivariate analysis 
that included age, gender, tumor stage, histologi-
cal type, smoking status and serum Ang-2, VEGF 
and the combination of both, we identified tumor 
stage, and high Ang-2 and the high
Ang-2/VEGF
 as 
independent prognostic factors for OS in NSCLC 
patients (Table 4).
Attending to these results, we performed an 
analysis considering three different prognostic 
models to ascertain the predictive power of 
tumor stage, high serum Ang-2 expression levels 
and the high
Ang-2/VEGF
 serum levels combined in 
the clinical outcome of NSCLC patients. In the 
first model, we considered the predictive abil-
ity of tumor stage (c-index 0.657; HR: 2.30; 
95% CI: 1.85–2.86; p < 0.001; model 1). Model 
2 gives the predictive ability of high serum Ang-2 
(c-index 0.707; HR: 1.88; 95% CI: 1.23–2.87; 
p = 0.003; model 2). Model 3 addressed the 
question whether high
Ang-2VEGF
 serum levels 
could also be considered a prognostic factor in 
NSCLC, with a c-index of 0.736 (HR: 1.69; 
95% CI: 1.16–2.47; p = 0.006; model 3).
Discussion
In recent years, despite major advances in 
NSCLC therapeutics, its unfavorable prognosis 
and short median overall survival time have yet 
to be overcome. The limited tumor response to 
conventional cytotoxic agents prompted the sci-
entific community to search for alternative thera-
peutic strategies. The improved understanding 
of molecular biology of cancer and mechanisms 
of tumorigenesis have allowed the identifica-
tion of several potential molecular targets and 
de velopment of novel targeted therapies [22].
Angiogenesis targeting agents were among 
the first to be recognized for potential benefit 
in NSCLC treatment. Several molecules with 
proved potent antiangiogenic activity in preclini-
cal studies have been developed [16,23], but most of 
them failed to show efficacy in clinical trials and 
were abandoned [17]. So far, only Bevacizumab, 
a humanized anti-VEGF monoclonal antibody, 
was approved for first-line treatment of advanced 
NSCLC and has become part of the guidelines of 
treatment in nonsquamous NSCLC [9]. In spite 
of what has been learned about its mechanisms 
of action, suitable biomarkers predicting patients 
who are likely to benefit from Bevacizumab treat-
ment remain elusive [24,25]. Originally, it was antic-
ipated that traditional markers of tumor angio-
genesis would predict outcome to Bevacizumab. 
However, neither VEGF expression levels nor 
tumor microvessel density were found to be pre-
dictive of treatment response, disease progression 
or death [17]. Moreover, recent studies suggest that 
targeting VEGF alone, although effective in elim-
inating some tumor blood vessels, only temporar-
ily halts tumor growth [26] and that overlapping 
and compensatory alternative angiogenic path-
ways provide escape mechanisms that likely limit 
the full potential of VEGF monotherapies [27,28].
These findings, along with the heterogeneous 
nature of the NSCLC, its development through a 
multistep process with potential crosstalk between 
multiple pathways and the interactions among the 
tumor and its stroma, leads to the assumption that 
the best strategy to substantially improve clini-
cal outcome and offer additional clinical benefits 
seems to be the inhibition of multiple cellular 
pathways in the tumor and in its milieu [29].
VEGF is the most potent and well-studied 
proangiogenic signaling factor, primarily pro-
duced by tumor cells, and its target structure is 
the tumor vasculature embedded in the stromal 
compartment [30]. Ang-2 exhibits a broad expres-
sion in the vasculature of human tumors, show-
ing limited postnatal expression in normal tissue 
(e.g., at sites of vascular remodeling like ovary, 
placenta, uterus) making it a tumor specific tar-
get for antiangiogenic therapies [31]. It has been 
proposed as a gatekeeper of VEGF, promoting its 
proangiogenic actions, thereby acting in concert 
to enhance tumor angiogenesis. While the VEGF 
and its receptors have been among the most exten-
sively targeted molecules in the angiogenesis field, 
clinical efforts targeting the more recently discov-
ered angiopoietin-Tie2 pathway are now gaining 
strength [13,32–34] and interestingly, some preclini-
cal studies suggest that treatment with a combina-
tion of Ang-2 and VEGF blockers provides bet-
ter inhibition of tumor growth than either single 
agent in a number of tumor models [11,26–27,31,34].
But the main problem subsists, that is, at this 
time, there are no reliable prognostic or predictive 
angiogenic markers in the NSCLC population and 
it is probable that several different biomarkers will 
Table 3. Multivariate logistic regression analysis of serum high expression of 
Ang-2, VEGF and both combined regarding the likelihood of presenting 
non-small-cell lung cancers.
Serum Ang-2 and VEGF  aOR 95% CI p-value†
High Ang-2 2.59 1.13–5.93 0.025
High VEGF 3.47 1.49–8.10 0.004
HighAng-2/VEGF  4.56 1.80–11.60 0.001
†p-value, aOR and 95% CI using logistic regression analysis, adjusted by age, smoking status and gender.
aOR: Adjusted odds ratio.
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Figure 2. Association of serum levels of Ang-2 (A), VEGF (B) and both combined (C) with overall 
survival in non-small-cell lung cancers by Kaplan–Meier curves.
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be required to address the unique problems posed 
by antiangiogenic drugs [35]. Identifying biomarker 
candidates for prospective evaluation in rand-
omized antiangiogenic trials, for efficacy, safety 
and cost considerations, remains an outstanding 
challenge in NSCLC and other cancers [36].
In the present study, we aimed to evaluate the 
prognostic significance of serum levels of Ang-2 
and VEGF in patients with NSCLC prior to treat-
ment. Moreover, due to the mutual influence that 
both molecules exert in tumor angiogenesis, we 
wanted to clarify if there is a co-dependent relation 
in both molecules serum levels and whether the 
combination of both factors could have a diagnos-
tic and/or prognostic impact in NSCLC patients 
or in the s usceptibility for NSCLC development.
Our results demonstrate that, although isolated 
serum Ang-2 or VEGF levels are associated with 
susceptibility to NSCLC cancer, the combination 
of both yields a more pronounced effect in the risk 
for NSCLC development. That is, patients with 
high
Ang-2/VEGF
 present a higher risk for NCSLC 
(OR: 4.66; p < 0.0001) than when considering 
Ang-2 or VEGF alone (OR: 2.63; p = 0.016; OR: 
3.27; p = 0.003, respectively). Moreover, we have 
shown these two markers combined are valuable 
in discriminating between healthy subjects and 
NSCLC patients. Our results demonstrate that 
high
Ang-2/VEGF
 expression levels are associated with 
a higher probability of NCSLC presence (AUC 
for high setting is 0.739; p < 0.0001), indicating 
the ability of these two markers in differentiating 
healthy individuals from patients with NSCLC.
We also evaluated the role of Ang-2 and 
VEGF expression levels as prognostic mark-
ers in NSCLC and assessed their joint effect 
in OS of NSCLC patients. Although we stud-
ied a Caucasian population, our results are in 
agreement with a previous study in an Asian 
population, of Park and co-workers [37], show-
ing that high levels of Ang-2 are associated with 
a lower OS (21.0 vs 42.6 months, respectively; 
log rank test, p = 0.001) in a univariate analysis. 
Conversely of Park’s results, our study also proved 
that Ang-2 is a prognostic factor in a Cox multi-
variate analysis. Moreover, when we consider the 
setting where both Ang-2 and VEGF expression 
levels are elevated simultaneously, a significant 
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poorer OS was demonstrated when comparing it 
with all the other patients (19.1 vs 35.2 months, 
respectively; log rank test, p = 0.005). This result 
maintains its consistency in a Cox multivariate 
analysis. High
Ang-2/VEGF
 independently determines 
survival, and its prognostic predictive ability 
(c-index 0.736) is better than for tumor stage or 
high serum levels of Ang-2 alone (c-index 657 vs 
c-index 0.707, respectively).
In summary, our results suggest that patients 
with combined high serum levels of Ang-2 
and VEGF can be regarded as a risk group to 
NSCLC development and bad prognosis.
Conclusion
In an interesting study, Goede et al. demon-
strated that high serum Ang-2 levels are associ-
ated with a poorer response to Bevacizumab, in 
colorectal cancer patients. Their findings suggest 
the possibility that patients with high circulating 
Ang-2 levels may be less responsive to anti-VEGF 
treatments and might therefore benefit from the 
combined blockade of Ang-2 and VEGF [24].
In view of our findings and after the proof of 
concept of Goede’s work, it is our belief that the 
assessment of combined serum levels of Ang-2 
and VEGF can be regarded as one step forward in 
the identification of a new predictive biomarker to 
be included in future NSCLC preclinical/clinical 
trials concerning antiangiogenic drugs.
The determination of this noninvasive pre-
dictive algorithm (serum levels of Ang-2 plus 
VEGF) is a very appealing approach, since 
samples are highly available, techniques are less 
expensive, readily performed, easily repeated and 
less biased than the more inconvenient, less prac-
ticable assessment in tumor tissue [17,22,38].
Although large-scale prospective stud-
ies are needed to confirm this hypothesis, this 
high
Ang-2/VEGF
 candidate biomarker should be 
regarded as a new integral biomarker in NSCLC, 
and be actively explored in trials of antiangio-
genic agents in patients, to get closer to the goal 
of improving and individualizing cancer therapy.
Future perspective
The advent of targeted agents that inhibit tumor 
specific biological pathways opened the door for 
a new era of NSCLC treatment. These include 
some very promising approaches, directed not 
only to specific targets in the tumor cells, but 
also toward the tumor stroma. Among these are 
the antiangiogenic strategies, where targets have 
been extensively investigated, with continuous 
novelties in the field being published in a regular 
basis. The main focus of antiangiogenic strate-
gies has passed through VEGF and its receptors, 
but in recent years, Ang-2 has come out to the 
light. Extensive research presents it as a credible 
partner/modulator of VEGF in tumor angiogen-
esis, making it a potential therapeutic target in 
several clinical trials involving antiangiogenic 
molecules, and the combination of agents that 
target simultaneously VEGF and Ang-2 might 
be more advantageous than targeting either of 
them alone.
Although antiangiogenic drugs are efficacious 
in unselected populations, increasing market 
competition between targeted therapies is likely 
to drive the growth of individualized treatments, 
with a central role for biomarkers. Albeit all the 
progresses made in this area, the quest for a bio-
marker that can lead the way when choosing the 
appropriate antiangiogenic treatment continues. 
We believe that for complex mechanisms such as 
tumor angiogenesis, there is the need to enlarge 
the search for biomarkers and that there is not a 
solo biomarker that can help to predict response, 
but rather a combination of biomarkers that will 
increase the chances of successful treatments.
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Table 4. Multivariate Cox regression model adjusted for predictable factors of 
overall survival in non-small-cell lung cancers.
Serum Ang-2 and VEGF aHR 95% CI p-value†
High Ang-2 1.88 1.23–2.88 0.003
High VEGF 1.16 0.748–1.80 0.509
HighAng-2/VEGF  1.69 1.16–2.47 0.006
†p-value, aHR and 95% CI using Cox regression analysis, adjusted by age, gender, tumor stage, histological 
type and smoking status.
aHR: Adjusted hazard ratio.
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EXEcUtiVE SUMMaRY
Background
 ●  The purpose of this study was to evaluate the prognostic relevance of combined serum Ang-2 and VEGF levels in 
non-small-cell lung cancers (NSCLC) patients and based on the proposed interplay between VEGF and Ang-2, it 
was also examined if there is a co-dependent relation in serum levels of both molecules in patients with NSCLC and 
whether the combination of both had a diagnostic and/or prognostic impact in these patients or in the likelihood of 
developing NSCLC.
Patients & methods
 ● Study population:
 ū  The study included 145 newly diagnosed and untreated Caucasian patients with NSCLC, from the North region of 
Portugal, admitted to the Portuguese Institute of Oncology of Porto.
 ū  Inclusion criteria were histological or cytological confirmed diagnosis of NSCLC, no previous treatment, no prior 
oncologic disease, available clinical data and Eastern Cooperative Oncology Group performance status ≤2.
 ū  The control group consisted of 30 Caucasian healthy individuals from the same geographic area as the NSCLC 
patients, recruited from the blood donor bank of the Instituto Português de Oncologia–Porto, free of malign, 
inflammatory and connective tissue diseases.
 ● Serum Ang-2 and VEGF analysis:
 ū  Serum levels of VEGF and Ang-2 were measured by means of an ELISA using the Quantikine Human VEGF ELISA kit 
and the Human Angiopoietin-2 Quantikine ELISA kit, according to manufacturer’s instructions;
 ū  To evaluate its roles as diagnostic and prognostic markers in NSCLC, samples were grouped in high Ang-2 or high 
VEGF serum levels of expression and low Ang-2 or low VEGF levels. Moreover, patients with high serum levels of 
both molecules were grouped separately in a highAng-2/VEGF subgroup.
Results
 ● Serum Ang-2 and VEGF in NSCLC patients and healthy control individuals:
 ū  Serum levels of Ang-2 were significantly correlated with serum levels of VEGF.
 ● Serum Ang-2 and VEGF levels and NSCLC clinical outcome:
 ū  High Ang-2, but not high VEGF, is associated with worst disease outcome; when comparing the setting of 
highAng-2/VEGF phenotype against all other samples, there is a marked decrease in OS.
 ● Serum Ang-2 and VEGF levels and likelihood of presenting NSCLC:
 ū  Individuals with high Ang-2 or high VEGF serum levels have higher probability of presenting NSCLC than 
individuals with low serum levels; individuals with highAng-2/VEGF present an almost fivefold increased likelihood of 
having NSCLC, regardless of age, gender and smoking status.
Conclusion
 ●  The assessment of combined serum levels of Ang-2 and VEGF can be regarded as one step forward in the identification 
of a new predictive biomarker to be included in future NSCLC preclinical/clinical trials concerning antiangiogenic 
drugs.
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ABSTRACT
The critical role of angiogenesis in tumor development makes its inhibition a 
valuable new approach in therapy, rapidly making anti-angiogenesis a major focus 
in research. While the VEGF/VEGFR pathway is the main target of the approved anti-
angiogenic molecules in NSCLC treatment, the results obtained are still modest, 
especially due to resistance mechanisms. Accumulating scientific data show that vessel 
co-option is an alternative mechanism to angiogenesis during tumor development in 
well-vascularized organs such as the lungs, where tumor cells highjack the existing 
vasculature to obtain its blood supply in a non-angiogenic fashion. This can explain the 
low/lack of response to current anti-angiogenic strategies. The same principle applies 
to lung metastases of other primary tumors. The exact mechanisms of vessel co-
option need to be further elucidated, but it is known that the co-opted vessels regress 
by the action of Angiopoietin-2 (Ang-2), a vessel destabilizing cytokine expressed 
by the endothelial cells of the pre-existing mature vessels. In the absence of VEGF, 
vessel regression leads to tumor cell loss and hypoxia, with a subsequent switch to 
a neoangiogenic phenotype by the remaining tumor cells. Unravelling the vessel co-
option mechanisms and involved players may be fruitful for numerous reasons, and 
the particularities of this form of vascularization should be carefully considered when 
planning anti-angiogenic interventions or designing clinical trials for this purpose. In 
view of the current knowledge, rationale for therapeutic approaches of dual inhibition 
of Ang-2 and VEGF are swiftly gaining strength and may serve as a launchpad to more 
successful NSCLC anti-vascular treatments.
INTRODUCTION
Cancer is a major health issue, constituting the 
second leading cause of death worldwide and expected to 
surpass heart diseases as the leading cause of death in the 
next few years [1, 2]. In 2013, the incidence of cancer 
cases worldwide was 14.9 million, with 8.2 million cancer-
related deaths. Lung cancer was the most common incident 
form of cancer, with an estimated 1.8 million new cases 
having deaths that exceeded those from any other type of 
malignancy worldwide, accounting for nearly one in five 
deaths (1.6 msillion deaths in total) [2]. Most lung cancers 
(~85%) are non-small cell lung cancers (NSCLC) which 
are divided according to two major histologic subtypes: 
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the non-squamous carcinomas (mainly adenocarcinomas) 
and the squamous-cell carcinomas [3]. The parenchyma 
and the stroma are the two almost-indistinguishable 
compartments that compose the NSCLC and build up the 
tumor microenvironment [4]. The stromal cells contribute 
to the development and expression of certain cancer 
hallmark capabilities, defined by Hanahan and Weinberg 
in 2011 [5]. Among these, angiogenesis assumes major 
importance, since rate-limiting steps in tumor progressions 
include gaining access to the host vascular system and the 
generation of a tumor blood supply to obtain oxygen and 
nutrients, growth factors and hormones [6].
ANGIOGENESIS AND CANCER
While the identification of massive vascularization 
in tumors dates back to 1863 [7] and the importance of 
tumor angiogenesis has been recognised since 1908 [8], it 
was only through the work of Folkman in the early 1970s 
that the scientific community acknowledge angiogenesis 
as a potential target to inhibit cancer progression [9-12]. 
The therapeutic potential of anti-angiogenic strategies 
boosted this field of research, placing angiogenesis as one 
of the major hubs of current cancer research. 
It is now widely accepted that most tumors and 
metastases originate as small avascular structures which 
must induce the development of new blood vessels from 
pre-existing ones in order to grow beyond a minimum 
size of 2-3 mm3 [6, 13]. To achieve this, tumors undergo 
an angiogenic switch, disrupting the equilibrium between 
pro and anti-angiogenic regulators and favouring pro-
angiogenic mechanisms. Signalling molecules induce 
quiescent endothelial cells to continuously sprout from 
existing blood vessels, thereby forming new vessels that 
help to sustain expanding neoplastic growth [6, 14, 15], 
according to the conventional model of angiogenesis 
known as angiogenic sprout [16].
Decades of research investigating the molecular 
basis of angiogenesis led to the discovery of a number of 
angiogenic molecules that promote tumor angiogenesis 
[15]. Of all the identified angiogenic pathways, the most 
critical appears to be the one involving the VEGF family 
and their receptors (VEGFR1-2-3) [17-19], although a 
number of other important molecules and their receptors 
have also proven to work in combination with VEGF/
VEGFR signalling in tumor angiogenesis [19]. These 
include the fibroblast growth factor receptors (FGFRs) 
family and their ligands, particularly FGF1 and FGF2, 
that induce the proliferation and migration of endothelial 
cells [20]; as well as the platelet-derived growth factor 
receptors (PDGFRs) and their ligands (PDGFs) that, 
either alone or in combination with FGF and VEGF, 
are associated with tumor vascularization in malignant 
disease, including NSCLC [21, 22] and the Ang-Tie-2 
system [19, 22]. Ever since the identification of VEGF 
as the first endothelium-acting specific cytokine in 1983 
[13, 23, 24], its overexpression has been found in several 
human tumors, including NSCLC [25-29]. More recently, 
scientists are gaining a better understanding of the many 
functions of this molecule in the tumor angiogenic process 
[29]: it triggers multiple signalling networks that enhance 
endothelial cell proliferation and survival, increases 
migration and invasion of endothelial cells, increases 
vascular permeability of existing vessels, and enhances 
chemotaxis and mobilization of bone marrow derived 
endothelial progenitor cells (EPCs) into the peripheral 
circulation [30, 31]. 
The growing acknowledgment of VEGF’s key role 
in tumor angiogenesis has made it an attractive target for 
therapeutic intervention in cancer. The VEGF pathway is 
a promising avenue in research that aims to uncover more 
effective, targeted anti-angiogenic strategies [23, 32]. The 
extensive investigation in this field has led to the study 
of several anti-angiogenic agents, including monoclonal 
antibodies to block VEGF and its receptor VEGFR2 and 
VEGFR tyrosine kinase inhibitors (TKIs) [33]. 
ANTI-ANGIOGENIC THERAPY AND 
LUNG CANCER
From the multitude of potential therapeutic options 
that target angiogenesis in NSCLC, [34] (Table 1), there 
are currently three anti-angiogenic compounds approved 
by EMA for the treatment of NSCLC. Bevacizumab, an 
anti-VEGF monoclonal antibody that blocks the binding 
of VEGF to its high-affinity receptors, was the first 
angiogenic inhibitor to complete clinical development, 
showing clinical benefit in patients with metastatic 
colorectal cancer when combined with chemotherapy 
[31, 33]. It was approved in 2006 for the treatment of 
advanced non-squamous NSCLC in the first line setting 
in combination with chemotherapy [29]. In 2014, 
ramucirumab, a fully humanized monoclonal antibody that 
targets angiogenesis by specifically binding to VEGFR-2 
with higher affinity than its natural ligand VEGF 
[35], was approved for the treatment of patients with 
metastatic NSCLC in second line setting, in combination 
with docetaxel [36]. In the same year, nintedanib, an 
oral medication that can simultaneously inhibit triple 
angiokinase, VEGFR, platelet-derived growth factor 
receptors (PDGFR), and fibroblast growth factor 
receptors (FGFR) signalling pathways, was approved to 
be used in combination with docetaxel in patients with 
locally advanced, metastatic, or locally recurrent NSCLC 
adenocarcinoma, after first-line chemotherapy [37]. There 
are also other potential agents that are under clinical 
evaluation, whether that be in the clinical trial stage or 
currently waiting for approval for treatment of metastatic 
or recurrent NSCLC [38, 39].
In spite of the impressive clinical efficacy of 
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bevacizumab, ramucirumab, and nintedanib in various 
cancer treatment settings, the results were relatively 
modest and limited [40]. In addition, the clinical use of 
VEGF/VEGFR blockers as anti- angiogenic therapy for 
patients with advanced NSCLC has been more challenging 
than anticipated by the preclinical experiments in which 
long-term benefit of VEGF/VEGFR inhibition was 
achieved [41]. Anti-angiogenic agents are usually given to 
all patients for the approved indications; in a high fraction 
of these patients, however, the tumor is intrinsically 
refractory to the anti-angiogenic therapy and the disease 
progresses ceaselessly [42]. Moreover, when there is no 
intrinsic resistance, acquired resistance to therapy can 
rapidly occur and limit the efficacy of the anti-angiogenic 
treatments [41, 43], and the clinical benefit of prolonging 
cancer patients survival with advanced disease becomes 
limited, often in the order of weeks or months [16, 44]. 
Tumor resistance to the anti-angiogenic therapies 
(whether intrinsic or acquired), represents a significant 
problem faced in routine clinical practice. The mechanisms 
underlying the response to these therapies are far from 
being clearly understood, further fuelling this active field 
of research [43]. Preclinical investigations have shed some 
light on the subject, and although different authors propose 
escape ways from angiogenic inhibitors that are somewhat 
distinct, some key features appear to be consensual among 
most of them; these features are likely to be involved in 
primary and acquired resistance and deserve consideration 
[16, 18, 41-43, 45]. One of such features is invasive (or 
metastatic) co-option of normal quiescent vessels without 
requisite of angiogenesis.
VESSEL CO-OPTION AND LUNG CANCER 
GROWTH
It is widely accepted that tumor progression is 
heavily dependent on angiogenesis. Much less understood, 
is the concept that angiogenesis is necessary for a tumor 
to become larger than a few millimetres and become 
clinically detectable, as some research has shown that 
angiogenesis is not always a pre-requisite for tumor 
growth [46]. Hence, one possibility for anti-angiogenic 
therapy resistance is that some primary and metastatic 
tumors are non-angiogenic, meaning that these tumors 
do not need angiogenic sprout to obtain an efficient 
blood supply [47]. Rather, the tumors use alternative 
vascularization mechanisms. For example, in vessel-dense 
tissues, the most likely route is hijacking the pre-existing 
normal blood vessels [42, 44, 48], and more aggressive 
tumors can undergo vasculogenic mimicry, a process 
by which tumor cells dedifferentiate to an endothelial 
phenotype forming structures that provide tumour cells 
with a secondary circulation system independently of 
angiogenesis [49].
When tumors arise in well-vascularized organs, 
their growth will rely on the invasion of host tissue. 
Enhancement of invasion and metastasis facilitates access 
to normal tissue vasculature, and cancer cells stay in 
close contact with the surface of blood vessels [39, 50, 
51]. This allows tumor cells to grow and migrate along 
quiescent normal vessels and take their oxygen and 
essential nutrients without obligate neovascularization, in 
Table 1: Angiogenesis inhibitors in non-small cell lung cancer (NSCLC)
Approved
Drug Target Indication
Bevacizumab VEGF First-line treatment of nonsquamous NSCLC with CT
Nintedanib VEGFR 2, FGFR 1-3, PDGFRα and β TKI
Second-line treatment of 
adenocarcinoma NSCLC with CT
Ramucirumab VEGFR-2 Second-line treatment of NSCLC with CT
On clinical trials or not approved
Drug Target
Vandetanib VEGFRs, EGFR, and RET 
Sunitinib VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET
Aflibercept VEGF
Sorafenib VEGFR, PDGFRs, FGFR, KIT, and RAF 
Motesanib VEGFRs, PDGFRs, and KIT 
Pazopanib VEGFRs, PDGFRs, FGFR, and KIT 
Cediranib VEGFRs 
Cabozantinib VEGFR, RET, and MET 
Axitinib VEGFRs, PDGFRs, and KIT 
CT - chemotherapy; VEGF - vascular endothelial growth factor; VEGFR - vascular endothelial growth factor receptor; FGFR 
- fibroblast growth factor receptor; PDGFR - platelet-derived growth factor receptor; KIT - stem cell factor receptor; FLT3 
- Fms-like tyrosine kinase-3; CSF-1R - colony stimulating factor receptor; RET - glial cell-line derived neurotrophic factor 
receptor; MET - met proto-oncogene;
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a process known as vessel (or vascular) co-option [42, 43, 
49]. These non-angiogenic tumors are a separate group of 
fast-growing malignancies with little apoptosis and very 
efficient mitochondrial metabolism [52]. This seems to be 
the case of tumors arising in the lungs, liver, and brain, 
areas where this form of vascularization appears to assume 
a major role [31, 50, 51, 53, 54]. This is also true for tumor 
metastasis that occurs through lymph and blood vessels 
and outgrow mostly in these vessel-dense organs [55-58].
In recent years, research related to angiogenesis 
has been massive; but on the contrary, there is a scarcity 
of research focusing on tumors that escape pathways of 
classical angiogenesis and use vessel co-option as an 
alternative blood supply for tumor growth. This has led 
to a dearth in information regarding the mechanisms and 
players involved in that process.
The first insights into the relationship between 
vessel co-option and lung cancer were made by Pezzella 
and co-workers, who described NSCLC that grew without 
morphological evidence of neoangiogenesis but with 
signs of normal tissue vessel exploitation [59]. They 
characterized these tumors as having an alveolar pattern, 
with tumor cell nests filling the alveolar spaces without 
destruction of the lung parenchyma. The only vessels 
evident in these tumors appeared to belong to the trapped 
alveolar septa [59]. Moreover, patients with alveolar 
pattern tumors presented a worse survival rate than 
their angiogenic counterparts. Later, when investigating 
the possible role of microvessel count in NSCLC as 
a potential marker of disease prognosis, Offersen and 
colleagues [60] identified the same special vascular 
pattern in 17 out of 35 NSCLC samples, thus confirming 
the description of Pezzella’s group. Their observations 
led them to the hypothesis that these alveolar tumors are 
nonangiogenic and invasive and exploited the pre-existing 
vascular beds. They also noted that some tumors exhibited 
only the alveolar pattern while other tumors presented a 
mixed alveolar pattern consisting of both alveolar and 
angiogenic features [60]. There was no correlation, 
however, between angiogenic or vessel co-option status 
and disease aggressiveness.
Taking into account the NSCLC growth patterns, 
Nia Sardari et al. suggested a modification of Pezzella’s 
classification according to morphological features, 
based on the biological properties of the tumor-lung 
interface, which is the region where the tumor expands 
and the tumor-stroma interactions are more active and 
homogeneous [61]. According to them, NSCLCs can 
be classified as having a destructive growth pattern 
(angiogenic growth pattern), papillary growth pattern 
(with preservation of the alveolar structure of the lung 
parenchyma at the interface with co-option of alveolar 
blood vessels with formation of stromal stalks and 
subsequent angiogenesis), and alveolar growth pattern 
(preservation of the alveolar structure of lung parenchyma 
with co-option of septal blood vessels and without 
evidence of new stroma formation at the interface). 
Moreover, they suggested that, in NSCLC, a low degree 
of ongoing angiogenesis is predictive of poorer prognosis 
[61, 62]. 
The hypothesis of co-option by lung metastases, 
which are often the main cause of death in many solid 
malignancies, was also proposed by Pezzella’s group 
back in the 1990’s. They observed that, regardless of 
the angiogenic status of the primary breast carcinomas, 
they could relapse as nonangiogenic tumors in the lungs. 
This was also true for lung metastases of human renal 
and colorectal carcinomas [56, 63, 64]. In a very recent 
study, Szabo and co-workers used cell lines from six 
different solid tumors, and showed that lung metastases 
Figure 1: Vessel co-option and Ang-2 regulation in cancer development in vessel dense tissues. A. In well vascularized 
organs, such as the lung, tumor cells grow and migrate along quiescent normal vessels (vessel co-option). B. Over time, tumor cells induce 
extreme changes in the co-opted vessels and ECs start to express Ang-2, leading to vascular disruption and vessel regression. C. Regression 
of the co-opted vessel associated with regression of the ECs generates a hypoxic core in the tumor centre, with massive tumor cell loss. This 
triggers the angiogenic switch, with the remaining tumor cells expressing high amounts of VEGF. D. VEGF expression induces a robust 
angiogenic response that ultimately rescues the tumor and allows its growth and progression.
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vascularize by co-opting the pulmonary microvasculature. 
The investigated cell lines incorporated the pre-existing 
host tissue capillaries within the alveolar walls, striping 
the epithelium from these co-opted alveolar walls [57]. 
Once there, the metastases expand as the malignant cells 
spread from one alveolar space to another. Their work 
not only shed some light on the mechanisms underlying 
this phenomenon, but it also raised some questions 
surrounding the biology of the nonangiogenic tumors, 
further advocating the need for additional exploration in 
this subject. 
VESSEL CO-OPTION AND ANGIOPOIETIN-2
In the lungs, the normal co-opted vessels trapped 
in the tumor can be very effective because they allow 
for more efficient tumor growth by exploiting the highly 
regular vascular network of the lungs and progressively 
filling the empty alveolar spaces [46]. Regardless of the 
efficacy of vessel co-option in sustaining tumor growth, 
the quiescent blood vessels co-opted by tumors suffer 
extreme changes over time [65]. While there is still debate 
if this due to a host defence mechanism against tumor 
development [47] or whether dependence on the survival 
of endothelial cells (ECs) [50], there is little doubt on the 
subsequent alterations observed. First, in the centre of 
the tumor, there is widespread regression of the co-opted 
vessels associated with the regression of the EC, turning it 
progressively hypoxic, with subsequent massive tumor cell 
loss [13, 32], followed by a robust de novo angiogenesis 
at the outer rim of the tumor, that rescues the remaining 
tumor cells in a later stage [13, 31]. 
The key regulator in the regression of the initially 
co-opted blood vessels appears to be Angiopoietin-2 
(Ang-2) [49, 53, 66], a cytokine that belongs to the 
Angiopoietins family, an important class of angiogenic 
molecules. It is a natural ligand of the endothelial tyrosine 
kinase-receptor, Tie-2, primarily synthetized and secreted 
by ECs at sites of vascular remodelling, like tumors, in a 
tightly regulated fashion [66-68]. Ang-2 is overexpressed 
in a number of tumors including NSCLC [69, 70], and 
there is also evidence that it is deeply involved in lung 
metastases homing and progression [71, 72]. Experimental 
evidence supports the notion that, soon after vessel co-
option, host vessels start to express high levels of Ang-2 
that acts through an endogenous autocrine loop mechanism 
that is context dependent [73, 74]. When it binds to its Tie-
2 receptor, it functions as a vessel-destabilizing molecule 
that converts mature vessels to a tenuous and plastic state 
by inducing loosening of endothelial cell interactions with 
pericytes and smooth muscle cells, leading to the loss of 
vascular integrity and increased vascular permeability. 
The ECs of such destabilized vessels can be prone to 
two fates, depending on the local cytokine milieu [74, 
75]. In the presence of VEGF, these cells will respond to 
the proliferating signals induced by the pro-angiogenic 
molecule and will migrate or proliferate, triggering a 
sprouting angiogenesis [13, 66, 70, 73, 76, 77]. In the 
absence of VEGF, however, the expression of Ang-2 
causes irreversible loss of vascular structures [76,78] 
with marked regression of the co-opted vessels, as is the 
case when tumors co-opt pre-existing vessels [77]. This 
is due to the fact that, without the pericytes coverage, 
the ECs of the Ang-2-unstable vessels will die [79] in 
a very similar fashion to what happens with primitive 
vessels during development [74]. This generates the 
hypoxic core and the apoptotic tumor cell loss observed in 
nonangiogenic tumors [47, 76], that presumably act as the 
initial stimulus for the molecular changes that culminate 
in VEGF expression by the remaining tumor cells and in 
neoangiogenesis [69], mediated both by VEGF and Ang-2 
[47] (Figure 1).
Not surprisingly, the discovery of the role of 
Ang-2 in tumor progression led to the suggestion that 
its inhibition could translate into clinically meaningful 
responses, opening the door to multiple approaches that 
have been used to experimentally inhibit Ang-2 as well 
as explore its effects on angiogenesis and tumor growth 
[80-82]. Pre-clinical models revealed that Ang-2 inhibition 
reduces the growth of a broad range of tumors. Although 
Table 2: Ang-1/Ang-2 and Tie inhibitors in development for NSCLC 
Drug Target Studies
Regorafenib VEGFRs, PDGFRs, FGFR, RET, Kit, B-Raf and Tie-2 NCT01187615
Trebananib
Fc fusion peptibody Ang-1 and Ang-2 NCT01666977, EudraCT 2011-001111-31
Foretinib VEGFRs, PDGFR β, FLT3, MET, and Tie-2 NCT01068587
MGCD265 VEGFRs, MET, and Tie-2 NCT02544633, EudraCT 2015-002070-21
AMG 780
Fully human
anti Ang-1/2 mAb
Ang-1 and Ang-2 NCT01137552
VEGFR - vascular endothelial growth factor receptor; PDGFR - platelet-derived growth factor receptor; FGFR - fibroblast 
growth factor receptor; RET - glial cell-line derived neurotrophic factor receptor; KIT - stem cell factor receptor; Tie - 
endothelial tyrosine kinase-receptor; FLT3 - Fms-like tyrosine kinase-3; B-Raf - serine/threonine-protein kinase; 
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some of the results were modest, some revealed to be 
very promising and there is now a robust pipeline of 
drugs targeting the Ang/Tie-2 system in different clinical 
trials phases (Table 2) [67, 78, 83]. Furthermore, with 
Ang-2 being required to render endothelium responsive 
to VEGF and with both molecules contributing to tumor 
angiogenesis and metastases [84, 85], there seems to be a 
more encouraging response to the straightforward question 
of whether co-targeting of both ligands in a bispecific 
manner would improve the outcomes of current anti-
angiogenic therapies [80, 83, 86-88]. 
VESSEL CO-OPTION AND CLINICAL 
IMPLICATIONS
The ability to identify tumors that make vascular 
co-option their primary source of blood supply does not 
envisage an easy task, hence why few strategies have been 
used to achieve this goal [48]. Research in the field has 
been scarce, especially when compared to the angiogenic 
field that has largely overshadowed alternative blood 
sources for tumor development. Moreover, much of the 
research has been performed in cell lines or murine models 
and only a few in human tissues [48]. While the findings 
are limited so far, what has been discovered highly 
advocates for unravelling the vessel co-option mechanisms 
and involved players. The precise identification of tumors 
that preferentially use this route to support growth and the 
factors driving them to switch from this to an angiogenic 
pattern may be crucial to delineate future cancer 
treatments for two main reasons. The first is that vascular 
co-option may represent a clever strategy by which tumors 
partly evade and resist conventional anti-angiogenic 
treatments [89]. Even if a treatment like bevacizumab is 
effective against one angiogenic factor such as VEGF, the 
therapy can still fail if this factor is not important for the 
endothelium in that given tumor, as appears to be the case 
in tumors that co-opt pre-existing vessels in NSCLC [45]. 
In these cases, vessel co-option may serve as a pathologic 
biomarker for selecting potentially nonresponsive patients 
[43]. There is also evidence that in some nonangiogenic 
tumors, cancer cells adapt by migrating more aggressively 
into normal tissue [42]; and when anti-angiogenic 
treatments are used indiscriminately, they may contribute 
to the selection of clones of nonangiogenic cells that will 
progress with a more aggressive behaviour [89, 90]. These 
features should be carefully considered when planning 
anti-angiogenic therapeutic interventions, suggesting the 
need for tailor-made treatments against such tumors. 
Secondly, anti-angiogenic compounds do not 
affect incorporated pre-existent vasculature or matured 
tumor vasculature, making targeting existing vessels on 
which the tumor growth relies, an attractive approach 
to accomplish tumor regression [91]. This is also of 
primordial importance in cases of metastases that establish 
in well-vascularized organs, since vessel co-option may 
constitute their primary feeding option [57]. Moreover, it 
can be speculated that in earlier stages of the tumor, the 
interval that mediates Ang-2 overexpression, co-opted 
vessels regression, and de novo angiogenesis seems to be 
the perfect therapeutic window for intervention using a 
dual-pronged approach with Ang-2 and VEGF blockers 
rather than in more advanced stages of the disease. This 
issue should be addressed by investigators developing pre-
clinical/clinical trials of drugs that target angiogenesis or 
envisage tumor arrest by anti-angiogenic strategies.
CONCLUSIONS
Anti-angiogenic strategies focusing on VEGF/
VEGFR in combination with chemotherapy marked 
a milestone in the field of cancer treatment, including 
NSCLC. However, a relevant number of patients are 
unresponsive or refractory to anti-angiogenic treatments. 
Some tumors obviate the need to generate angiogenesis 
by co-opting host mature vessels and growing along 
them, using them as blood sources. Vessel co-option is a 
mechanism that may help explain the limited success of 
anti-angiogenic therapy in these patients in an adjuvant 
setting. 
Thus far, the only growth factors proven to be 
associated with vessel co-option are VEGF and Ang-
2. This lack of information is likely due to the limited 
number of studies examining this subject. Ang-2 seems to 
have a particularly critical role in the process, but is also 
an extremely laborious study topic due to the complexity 
of its functions and regulation, which are both highly cell 
context dependent. 
Tumors that grow in non-angiogenic fashions 
through exploitation of pre-existing vessels are non-
responsive to anti-angiogenic molecules and raise a 
number of concerns in terms of treatment. First, little is 
known about the modifications a neoplastic cell must go 
through in order to co-opt a blood vessel, which is a huge 
obstacle for strategies that aim to interfere with this step in 
tumor progression. Second, once the tumor is committed 
to vascular co-option pathway, an effective way of 
blocking tumor progression would be to target existing 
tumor vasculature; this would require the availability of 
tumor-vessel specific targeting agents, however, and the 
few candidates that have been identified so far have failed 
to prove their clinical efficacy. 
All of these concerns reinforce the need for better 
understanding of the mechanisms and molecular players 
underlying vessel co-option during tumor development 
within the proper biologic context. This would not only 
explore more assertive cancer treatments and help with 
the identification of tumors where vessel co-option is 
the growth support (instead of angiogenesis), but could 
also help identify patients who may be nonresponsive to 
current anti-angiogenic treatments. Additionally, it could 
open doors to novel areas of NSCLC research at both the 
Oncotarget7www.impactjournals.com/oncotarget
molecular and microanatomical level.
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Until the late 1990s, treatment of NSCLC followed the simple algorithm of 
platinum based combination therapy, with or without surgery and/or radiation 
therapy, depending upon tumor stage, irrespective of histological subtype and without 
any option for further lines of treatment [115]. The limited tumor response to 
conventional cytotoxic agents and the short median OS of NSCLC patients impelled the 
scientific community to search for alternative therapeutic strategies that could have 
better performances in limiting NSCLC disease progression. This goal was partially 
achieved when increased knowledge on the molecular biology of cancer and on the 
complex mechanisms that underlie NSCLC tumorigenesis revealed that lung cancer is 
not a single entity, but rather a collection of diseases, identifiable by its molecular 
abnormalities [116]. This constituted the launchpad to the era of personalized 
medicine and promptly, several potential molecular targets were identified, and novel 
targeted therapies were developed based on the inhibition of those targets [116].  
Angiogenesis is a hallmark of cancer, and agents targeting key molecules in this 
crucial process for tumor development were among the first to be recognized for 
potential benefit in NSCLC treatment. The rationale behind the alleged success that 
angiogenesis hindrance would bring into NSCLC treatment was very straightforward: 
angiogenesis is stroma related, and therefore, transversal to all types of cancers, and 
tumors cannot sustain growth without it [10,11,20,117].  
The best studied pathway in the generation of a robust tumor vasculature is VEGF 
and its receptors (VEGFRs) and not surprisingly, the first approved antiangiogenic 
treatments were bevacizumab and ramucirumab, two compounds that block VEGF and 
VEGFR2, respectively, administered in combination with cytotoxic chemotherapy 
[35,39,41,42]. These agents primarily promote stable disease, targeting immature 
blood vessels, and normalizing tumor vasculature, improving drug delivery to tumor 
stroma [62,118]. But these treatments, although exhibiting a substantial improvement 
in NSCLC median OS, felt short on the high expectations generated around them; there 
is a considerable subset of patients who do not respond or even experience 
progression under therapy [39].  
Insights into the mechanisms that may be responsible for the weak responses to 
anti-VEGF pathway inhibitors have shown that overlapping and compensatory 
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alternative angiogenic pathways provide escape routes that probably limit the full 
potential of VEGF monotherapies [46], and revealed that the proangiogenic cytokine 
Ang-2 is likely one of the most important regulators of these processes; Ang-2 
overexpression is part of an ‘‘angiogenic rescue’’ when VEGF-VEGFR2 signalling is 
blocked during tumor progression, being responsible for compensatory tumor 
revascularization and exaggerating malignant tumor progression by increasing local 
invasion and accelerating metastasis [119-123]. So, it was proposed that Ang-2 
inhibitors, both as single agents or in combination with chemo- or anti-VEGF therapy, 
could efficiently mediate anti-tumor effects, and several experimental models were 
developed that confirm this theory [101,118].  
After extensive bibliographic research, we pictured another important obstacle to 
the success of anti-angiogenic monotherapies that target VEGF pathways. Several 
studies suggest that some NSCLC, with more aggressive phenotypes, obviate the need 
to generate angiogenesis by co-opting host mature vessels and growing along them, in 
a process known as vessel co-option [51, 134]. Vessel co-option may be a potential 
explanation as to why approved NSCLC antiangiogenic therapy in many cases does not 
appear to be as beneficial as initially expected. Mature, non-angiogenic vessels are 
intrinsically different from the immature vessels that originate from angiogenesis. They 
are characteristically surrounded by tight pericyte coverage, showing low angiogenic 
activity, if any. This constitutes a handicap to therapies aiming to halt tumor 
development through the blockade of VEGF or its receptors, since there is no obvious 
expression of these molecules in the tumor stroma during the first steps of tumor 
progression. Intriguingly, it is observed that blocking VEGF signalling increases co-
option and growth of satellite tumors in some tumor models [135].  On the contrary, 
correlative expression of Ang-2 by ECs in the context of tumor vessel co-option 
supports the concept that this cytokine has a dominant biological role in this form of 
tumor vascularization [62], and it has been proposed that it is the main responsible for 
mature vessel destabilizing actions, which, ultimately, generates a hypoxic core in the 
tumor, that is posteriorly rescued by an increased expression of VEGF, which induces a 
robust angiogenic response [136].  
Assuming the above scenario, it can be speculated that in earlier stages of the 
tumor, the interval that mediates Ang-2 overexpression, co-opted vessels regression, 
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and angiogenesis seems to be the perfect therapeutic window for intervention using a 
dual-pronged approach with Ang-2 and VEGF blockers rather than in more advanced 
stages of the disease, serving as a launchpad to more successful NSCLC anti-vascular 
treatments. 
The improved efﬁcacy when VEGF and Ang-2-targeting therapies are combined is 
now solidly established in preclinical models, and several Ang2-targeting drugs are in 
clinical trials [62], with very encouraging results, as previously exposed 
[53,64,69,76,87,100-107].  
But regardless of the promising success of the new anti-angiogenic approaches, 
that inhibit both VEGF and Ang-2-associated pathways, an important issue subsists. 
Considering the high cost of these therapies, specific biomarkers able to discriminate 
patients for whom therapy with antiangiogenic inhibitors may be most beneficial and 
the importance of these as prognostic factors in NSCLC are not only a clinical necessity, 
but are also an economic requirement [124]. Extensive biomarker programs have been 
built into numerous clinical studies, and originally, it was anticipated that traditional 
markers of tumor angiogenesis would predict outcome to angiogenic inhibitors. 
However, neither VEGF expression levels, nor tumour microvessel density (MVD) were 
found to be predictive of treatment response, disease progression or death [125]. This 
boosted a forefront of basic and applied vascular biology research, aiming to find 
alternative biomarkers that may guide future pharmaceutical development to improve 
antiangiogenic interventions. 
The induction of Ang-2 mRNA in tumor endothelium has made Ang-2 a very 
attractive circulating biomarker of angiogenic activation during tumorigenesis, and 
some authors addressed the correlation between mRNA and Ang-2 expression in 
tumor tissue, the protein circulating levels and cancer development and metastasis, 
although few of them were able to document a correlation between this molecule and 
disease clinical features or prognosis in lung cancer [126,127,128,129]. 
Taking into account the well-established correlation between Ang-2 mRNA and 
Ang-2 expression in the context of tumorigenesis, the present study aimed to evaluate 
the prognostic significance of Ang-2 mRNA detection in the cell fraction of peripheral 
blood of patients with NSCLC, prior to treatment, using qRT-PCR. Moreover, it 
intended to evaluate the possibility of using Ang-2 mRNA levels as an independent 
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prognostic factor for NSCLC. Our results demonstrate that high circulating Ang-2 mRNA 
levels are a significantly unfavourable prognostic factor in NSCLC.  When considering 
all NSCLC stages, patients with high circulating Ang-2 mRNA levels present diminished 
OS when compared to those with low mRNA expression, and this difference is even 
more notorious when considering only patients with advanced stage disease (with 
distant metastasis), the most suitable candidates to current antiangiogenic therapies. 
Moreover, mRNA levels independently determine survival, and its prognostic 
predictive ability increases when modelled in a simple and easy to apply nomogram 
with NSCLC staging, patients’ smoking status and Ang-2 mRNA levels. Our findings are 
in agreement with a similar study from Takanami et al, which measured Ang-2 mRNA 
levels in NSCLC tissue, and observed that higher Ang-2 tissue mRNA levels also confer 
worst disease prognosis [129].  
Taken together, our observations prompted us to think that detection and 
quantification of circulating Ang-2 mRNA in blood samples, along with proper NSCLC 
staging, could serve as a biomarker of prognosis in NSCLC, as well as a determinant of 
the angiogenic state of the tumor. This hypothesis is based on the fact that Ang-2 
shows limited postnatal expression in normal tissues, but exhibits broad expression 
and prominent upregulation in the tumor milieu [53]. This high Ang-2 expression is 
strongly induced by ECs, and regulated at the transcriptional level, through the 
upregulation of Ang-2 mRNA [62], and hence, circulating Ang-2 mRNA levels 
theoretically reflect the overall angiogenic activity of the tumor. This biomarker would 
offer major advantages over tissue based markers, since blood Ang-2 mRNA samples 
are easily accessible, and allow the ability to carry out continuous, non-invasive 
assessments over time and most important, do not rely on the availability of adequate 
surgical or biopsy specimens, so difficult to obtain in NSCLC. 
Keeping in mind that Ang-2 and VEGF are inseparable proteins in tumor angiogenic 
settings, and the assumed relationship between both, the second part of this study 
aimed to evaluate whether the serum expression levels of these proteins are 
correlated in NSCLC patients, and if this has an impact in the disease OS. The 
evaluation of the impact of combined serum Ang-2 and VEGF levels as a diagnostic tool 
in NSCLC and its relation with the likelihood of an individual to present NSCLC were 
secondary endpoints of this study. 
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Similarly to what was previously described by Park and co-workers [128], we 
found that serum Ang-2 levels inversely correlate with OS, but unlike Park’s results, 
this is also true after a multivariate analysis, adjusted by age, gender, tumor stage, 
histological type and smoking status.  Moreover, serum levels of VEGF alone did not 
correlate with prognosis in the studied NSCLC population. An interesting finding of our 
experiments was that grouping the samples with concomitant high levels of Ang-2 and 
VEGF (HighAng-2/VEGF), seems to confer a cumulative decrease in OS, suggesting that 
when both Ang-2 and VEGF are elevated in serum, the prognostic effect in the disease 
is more pronounced than the elevation of each marker by itself. These results are not 
surprising, given the recognized tight interplay of the VEGF and the Ang-Tie2 pathway 
in vessel physiology and pathology. So, we propose that both high Ang-2 and HighAng-
2/VEGF serum levels could serve as non-invasive biomarkers of poor prognosis in NSCLC.  
In the current era of antiangiogenic targeted therapies, the analysis of circulating 
factors may not only help to determine prognosis but also direct the use of targeted 
therapies [130], yielding personalized information on tumor biology and help to 
predict tumor responses to angiogenic inhibitors. Herein, we propose two different 
prognostic biomarkers for NSCLC overall survival, high circulating Ang-2 mRNA levels 
and combined high serum levels of VEGF and Ang-2, which we believe that deserve 
further exploitation as predictive biomarkers of NSCLC responses to combined 
antiangiogenic targeted therapies. Circulating predictive biomarker assays would be of 
great interest in the clinical practice, mainly because of the simplicity of sampling and 
the future potential of automation of the technical methods for clinical applicability. 
Moreover, this kind of tests would allow the tracking of tumor state in the course of 
the disease. 
Another interesting finding of our study was that individuals with isolated high 
Ang-2 or high VEGF serum levels, have higher probability of presenting NSCLC than 
individuals with low serum levels, and individuals with the HighAng-2/VEGF phenotype 
present an almost 5 fold increased likelihood of presenting NSCLC. The conclusions are 
valid regardless of age, gender and smoking status. In summary, our results suggest 
that individuals with high serum levels of Ang-2 and VEGF (alone or in combination) 
can be regarded as risk groups for having NSCLC.   
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Given the high prevalence of NSCLC and low survival rates, efforts have been 
focused not only in the development of more efficacious targeted therapies, but also  
on developing screening protocols for the high risk population likely to develop NSCLC, 
since early detection of lung cancer is an important opportunity for decreasing lung 
cancer mortality.  
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines 
in Oncology (NCCN Guidelines) for Lung Cancer Screening provides recommendations 
for the selection of high risk groups of individuals, candidates for lung cancer 
screening, performed with low-dose computed tomography (LDCT), based upon the 
results of multiple randomized trials that assess whether LDCT screening decreases 
disease-specific mortality [131]. According to these guidelines, LDCT screening should 
be considered for high-risk individuals who are potential candidates for definitive 
treatment. Current or past history of tobacco smoking has been firmly established as a 
risk factor for lung cancer development with a relative risk for lung cancer being 
approximately 20-fold higher for smokers than for nonsmokers. So, in the NCCN 
Guidelines, current and former smokers aged 55 to 74 years with a 30 or more pack 
year history of smoking tobacco are selected as the highest-risk group for lung cancer 
and are recommended for screening. Former smokers with a 30 pack-year smoking 
history who quit smoking less than 15 years ago are also included in this highest-risk 
group [131]. Individuals  aged aboveŽ50 years and with a history of 20 pack-year 
smoking and one additional risk factor, such as radon exposure, occupational 
exposure, cancer history, family history of lung cancer, disease history (COPD or 
pulmonary fibrosis) with absence of symptoms or signs of lung cancer fall in the same 
levels recommendation.  
However, LDCT scans have low specificity, only 61%, when screening for lung 
cancer. For approximately every one true positive scan there are 19 false positive 
scans [132]. This configures a problem in the generalization of lung cancer LDCT 
screening for psychological and economic reasons. On one hand, a false positive result 
induces unnecessary anxiety and fear in the screened individual and his family, and on 
the other hand, it can result in costly unnecessary follow-up interventions, including 
invasive biopsies or surgical resection [133].  
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A way to improve the low specificity value that LDCT screening has on its own, 
would be its association with easy-to-obtain molecular biomarkers of lung cancer risk 
that could help to define a more refined subset of individuals at higher risk of 
developing NSCLC. We believe that one of such risk biomarkers could be the presence 
of the HighAng-2/VEGF phenotype in high risk individuals. It seems like a suitable candidate 
because of its association with an almost 5-fold increased likelihood to present NSCLC 
and considering this is a circulating biomarker, it would be easy to build minimally-
invasive, cost-effective tests aiming its detection in peripheral blood samples.  
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5.  FUTURE PERSPECTIVES 
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Based on the assumption that angiogenesis is a common feature of all tumors and 
that it is quite a homogeneous process, tumor angiogenic inhibitors have been 
developed to apply to most solid tumor types, irrespective of the intrinsic biological 
characteristics of each tumor. As a consequence of this simplified vision of 
angiogenesis, clinical development of tumor antiangiogenics was not biomarker-based, 
and the original promise of success of the current antiangiogenic treatments stumbled 
across a great diversity of mechanisms of resistance in different patient settings.  
The most obvious candidate to join VEGF pathway blockade in the quest for 
improved antiangiogenic strategies is the inhibition Ang-2-Tie2 axis, which is involved 
in the resistance to Anti-VEGF(R) agents. Based on current data, the combination of 
Ang-2 and VEGF targeted modalities would yield more effective results than either 
alone. Furthermore, targeting Ang-2 would add an extra layer of tumor 
microenvironment effects by inhibiting the recruitment of TEMs that have been shown 
to aid tumor and vascular growth. Clinical development and validation of these new 
strategies would receive a great and decisive advantage from the availability of 
biomarkers to select the patients who, in a given patient population, are more likely to 
benefit from these new drugs and strategies. 
Our results show that high circulating Ang-2 mRNA levels, high serum Ang-2 and 
the combination of serum high levels of Ang-2 and VEGF, measured before treatment, 
confer worst OS to NSCLC patients. So, we propose that they can serve as prognostic 
biomarkers of survival in NSCLC, regardless of treatment. Large-scale prospective 
studies need to be conducted to confirm our results.  
We speculate that these prognostic biomarkers could as well be candidates to 
predictive biomarkers of response to angiogenic inhibitors. To demonstrate that a 
biomarker is predictive of treatment benefit, the study requires biomarker status on all 
patients as well as patients who were treated with the agent of interest and patients 
not so treated, preferably in the context of a randomized study. Therefore, we propose 
the inclusion of the measurements of the combined serum levels of Ang-2 and VEGF 
and of the circulating levels of Ang-2 mRNA in current and future randomized clinical 
trials of antiangiogenic agents targeting VEGF and Ang-2 pathways, so the predictive 
role of these biomarkers can be elucidated. To be confirmed, our hypothesis would 
help to balance efficacy, toxicity and cost of these novel therapies. 
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The acknowledgement of vessel co-option as an alternative mechanism that solid 
tumors use to avoid angiogenesis, opened doors to an entirely new and very 
interesting field of research, that raises many questions and  brings few answers. First, 
little is known about the modifications a neoplastic cell suffers in order to be 
committed to vessel co-option. Second, if the tumor is committed to the vascular co-
option pathway, an effective way of blocking tumor progression would be to target 
existing tumor vasculature, but currently, there are no mature tumor-vessel specific 
targeting agents. All of these concerns reinforce the need for a better understanding of 
the mechanisms and molecular players underlying vessel co-option during tumor 
development within the proper biologic context. This would not only explore more 
assertive cancer treatments and help with the identification of tumors where vessel 
co-option is the growth support (instead of angiogenesis), but could also help identify 
patients who may be nonresponsive to current antiangiogenic treatments. 
Additionally, it could unravel novel areas of NSCLC research at both the molecular and 
microanatomical level. 
Finally, we intend to delineate a population based study of lung cancer screening, 
selecting a sample population with the high risk factors defined in the NCCN screening 
guidelines and applying the LDCT scans to all of the individuals, and simultaneously 
determining the combined serum levels of Ang-2 and VEGF, in order to assess the 
value of HighAng-2/VEGF as a biomarker of lung cancer presence.  
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